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1 Introduction
1.1 The islets of Langerhans
In 1869, German pathologist Paul Langerhans discovered the cell-clusters in the pancreas which
we today know as the Islets of Langerhans. Those nests of cells are responsible for the endocrine
functions of the organ (Langerhans, 1869). Around 1 million islets are distributed throughout
the human pancreas. Their total contribution to the mass of the organ is around 2 % to 3 %. Five
types of endocrine cells are known to exist in each of those micro-organs: Alpha-cells produce
glucagon, which promotes glycogenolysis in the liver; beta-cells secrete insulin and amylin,
which are needed for glucose uptake and inhibition of lipolysis; gamma-cells release pancreatic
polypeptide, an important self-regulating factor; delta-cells are responsible for somatostatin, an
inhibiting polypeptide; and epsilon-cells account for ghrelin, which has an influence on appetite.
The respective amount of every cell type differs between species, but beta-cells usually form
the majority, followed by the alpha-fraction (Jones and Persaud, 2010) (table 1.1).
type amount product effect
alpha 20 % to 30 % glucagon increases glycogenolysis in the liver
beta ˜60 % insulin
amylin
necessary for glucose uptake, inhibits
lipolysis
synergistic to insulin, inhibits glucagon
gamma <5 % pancreatic
polypeptide
regulates pancreatic secretion
delta ˜10 % somatostatin inhibits the release of other hormones
epsilon ˜1 % ghrelin stimulates appetite and the release of
growth hormone
Table 1.1: Endocrine pancreatic cells (Jones and Persaud, 2010).
Insulin is the only hormone which is able to actively lower blood glucose levels and to inhibit
lipolysis. Therefore, the insulin-producing beta-cells are the lynchpin of the pathophysiology
of diabetes mellitus.
1.2 Diabetes mellitus
1.2.1 Definition and aetiology
Diabetes mellitus is a metabolic disorder defined by chronic hyperglycaemia. However, there
are various aetiological reasons for the pathological glucose homeostasis. Most common are
1
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diabetes mellitus type 1 and 2. Type 1 diabetes is characterised by destruction of the beta-cells
leading to a lack of insulin. This destruction takes place because of autoimmune processes or
happens idiopathically. In contrast, type 2 diabetes occurs due to resistance of tissue against
insulin action on the one hand and an inadequate secretion of the hormone on the other hand.
Furthermore, diabetes can be caused by various genetic defects, diseases of the exocrine pan-
creas, endocrinopathies, infections and it can also be induced by drugs. Diabetes occuring
during pregnancy is called gestational diabetes (American Diabetes Association, 2003). The
different variations of the disease and their aetiology are summarised in table 1.2.
Form Aetiology
I - Type 1 A. Immune mediated
B. Idiopathic
II - Type 2 Insulin resistance, relative insulin deficiency, secretory defect
III - Other forms A. Genetic defects of beta-cell function
B. Genetic defects in insulin action
C. Diseases of the exocrine pancreas
D. Endocrinopathies
E. Drug- or chemical-induced
F. Infections
G. Uncommon forms of immune-mediated diabetes
H. Other genetic syndromes sometimes associated with diabetes
IV Gestational diabetes mellitus
Table 1.2: Aetiology of diabetes mellitus (American Diabetes Association, 2003).
There is an involvement of a genetic component in both type 1 and 2 diabetes. However, the
predisposition is even stronger for type 2 than for the autoimmune form of type 1. Genetically
characterised forms of type 2 diabetes include maturity onset diabetes of the young (MODY),
defects in the insulin or insulin receptor gene as well as mutations in mitochondrial genes and
in glucose transporters (Kahn et al., 1996). The genetic predisposition of diabetes can be un-
derstood by the following scientific facts: It is estimated that the risk for developing type 2
diabetes is 10-fold higher for a monozygote twin if the other twin has the disease, it is 3.5-fold
higher for first-degree relatives and for second-degree relatives 1.5-fold higher in comparison to
the general population (Rich, 1990). Furthermore, obesity is an important risk factor for type 2
diabetes and it is suspected that there is an important link between adiposity and diabetes apart
from a genetic one (Eckel et al., 2011). Hence, life-style factors and genetics play an important
role in predisposing an individual to diabetes mellitus.
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1.2.2 Epidemiology
Diabetes mellitus plays a major role in global health. A large meta study by the International
Diabetes Federation depicts the global prevalence of the disease and estimates its development
for adults aged 20 to 79 years. The so-called Diabetes Atlas was published for the first time in
the year 2000. Since then, it has been updated regularly. Data from hundreds of studies world-
wide are used. Most of them are taken from peer-reviewed publications, but also national health
surveys and official reports from international agencies and government surveys are included
(Guariguata et al., 2011).
According to the atlas more than 371 million people worldwide were suffering from diabetes
in the year 2012 (International Diabetes Federation, 2012) and incidence is rapidly increasing.
In 2003 the federation predicted a total of 334 million diabetic people for 2025 (International
Diabetes Federation, 2003). As this number has already been surpassed, new estimates expect
a total of 552 million people to be affected by the disease for the year 2030.
Whereas 5 % to 10 % of patients suffer from type 1 diabetes, the vast majority of diseases
(around 85 % to 95 %) are categorized as type 2 (International Diabetes Federation, 2012).
Thus, the rising incidence in diabetes is mainly caused by new cases of type 2. For example,
from 1990 to 2010 the number of patients aged 18 to 79 in the USA almost tripled (Geiss and
Gowie, 2010).
Based on data of the AOK, a German health insurance company which represents around one
third of Germany’s population, the prevalence of diabetes rose from 5.9 % in 1998 to 9.7 % in
2009 (Hauner et al., 2007; Ko¨ster et al., 2012). Furthermore, the prevalence turned out to be
markedly higher in people aged 60 years and above. While below 5 % at the age of 40 were
treated because of diabetes in the year 2004, it was around 20 % aged 60 depending on the sex
(Hauner et al., 2007). Specifically regarding the prevalence of diabetes type 2, a meta study
merged the data of five regional studies dating from 1997 to 2006. The results showed a dif-
ferent number of type 2 diabetics regionally varying from 5.8 % to 12 % (Schipf et al., 2012).
In addition, the rising incidence of diabetes type 2 in children and young adults should be con-
sidered. A study with 520 adipose subjects aged 9 to 20 years showed that 1.5 % suffered from
type 2 diabetes and 5.8 % had an impaired glucose tolerance (Wabitsch et al., 2004). Both,
ageing of the population and the growing number of obese people are main factors of growing
diabetes type 2 incidence and prevalence.
1.2.3 Symptoms and long-time consequences
Symptoms of considerable hyperglycaemia are polyuria, polydipsia, loss of weight and blurred
vision. Severely high blood sugar levels cause life-threatening ketoacidosis and hyperglycaemic
nonketotic coma. In the long run its influence on the vascular system leads to macro- and mi-
croangiopathy. As a consequence of the macroangiopathy the incidence of cardial, cerebral and
3
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peripheral vascular disease is increased in patients suffering from diabetes, manifesting in a
higher rate of myocardial infarctions and strokes. Symptoms of microangiopathical alterations
are retinopathy, nephropathy and neuropathy. In consequence, patients are in danger of losing
their eyesight, kidney failure, ulcers and amputations as well as gastrointestinal and genitouri-
nary dysfunction (American Diabetes Association, 2003). An overview of the relative risk for
several long-time complications compared to nondiabetics / the general population is shown in
table 1.3.
complication relative risk
myocardial infarction 3.7 (males)
5.9 (females)
cardiovascular death 9.1 (patient < 30 years old at diagnosis)
2.3 (patient > 30 years old at diagnosis)
stroke 2 - 4
blindness 5.2
renal failure 12.7 (males)
amputation 22.2 (lower limbs)
foot ulcers 45
Table 1.3: Complications of diabetes mellitus (DDG, 2004).
1.2.4 Treatment of diabetes mellitus
The main aim of diabetes therapy is to reduce acute complications as well as long-term conse-
quences of the disease. This goal is achieved by maintaining blood glucose control. Since the
fist extraction of insulin from a canine pancreas (Paulescu, 1921), exogenously produced hor-
mone is used as a subsitute for patients suffering from diabetes (Banting et al., 1922). Type 1
diabetics rely on exogenous insulin in the vast majority of cases. Thus, substitution is the main
therapeutic strategy. Other options, which are not in routine clinical practice, are pancreas and
islet transplantation (DDG, 2011). Patients suffering from type 2 diabetes are usually treated
with oral antidiabetics without or in combination with insulin. Those drugs include sulphony-
lureas and their analogs, biguanides, alpha-glucosidase inhibitors, glitazones, DPP-4 inhibitors
and GLP-1 agonists (DDG, 2009). Several studies show the efficacy of diabetes therapy. In the
Diabetes Control and Complications Trial researchers compared the risks of long-term com-
plications between type 1 diabetics who were treated intensively and those who received con-
ventional therapy. The study showed that retinopathy can be reduced by 76 %, nephropathy by
56 % and neuropathy by 69 % (The Diabetes Control and Complications Trial Research Group,
1993). The UK Prospective Diabetes Study revealed a similar benefit for type 2 diabetics. A
25 % risk reduction for microvascular disease, 12 % for any diabetes-related endpoint, 10 % for
4
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any diabetes-related death and 6 % for all-cause mortality were found (UK Prospective Diabetes
Study (UKPDS) Group, 1998).
Besides, changes in life-style represent a very important pillar of the treatment. Losing weight,
physical activity and healthy nutrition can reduce the symptoms of diabetes or even delay the
onset (Narayan et al., 2002).
However, the major risk of therapeutic blood glucose control is hypoglycaemia. This severe
draw-back should be accounted for in patient education and individual therapy regimes (DDG,
2009; UK Prospective Diabetes Study (UKPDS) Group, 1998).
1.2.5 Pathophysiology of diabetes mellitus type 2
Diabetes mellitus type 2 is a multi-factorial disease, consisting of a lowered insulin sensitivity in
the insulin-dependent organs, raised gluconeogenesis in the liver, an impaired insulin secretion
in the pancreas as well as apoptosis of the beta-cells (American Diabetes Association, 2003).
Influences are shown in figure 1.1.
There are several mechanisms which lead to insulin resistance. Receptor binding and post-
Figure 1.1: Diabetes mellitus type 2 as a multi-factorial disease (Kahn et al., 1996). There are
genetic initiation factors which predispose an individual to diabetes. The progress
from a physiological glucose homeostasis to a manifest diabetes is furthermore ac-
celerated by several progression factors such as obesity, diet and activity. A relative
lack of insulin due to decreased secretion and sensitivity leads to hyperinsulinaemia
and a state of impaired glucose tolerance. The beta-cells take damage and become
dysfunctional, leading to an absolute lack of insulin and manifesting the disease.
binding defects play an important role, including defective glycogen synthesis and lowered
insulin receptor tyrosine kinase activity. Furthermore, the insulin receptor is down-regulated by
5
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chronic hyperinsulinaemia and its signal transduction is impaired.
At the beginning of the disease an elevated insulin secretion compensates for the insulin resis-
tance. In response to raised fasting blood glucose levels the beta-cells are able to increase the
insulin concentration up to a blood glucose level of 140 mg dl−1. A peak is reached where the
insulin concentration in the patient suffering from diabetes type 2 is up to 2.5-fold higher than
in nondiabetic subjects. However, higher blood glucose levels cause the insulin production to
lower quickly, resulting in a minimal response from 200 mg dl−1 onwards.
Physiologically, the hepatic glucose output is down-regulated by hyperinsulinaemia and hyper-
glycaemia. For this regulation becomes insufficient, subjects with fasting hyperglycaemia also
show an elevated gluconeogenesis in the liver (DeFronzo, 2004).
Another consequence of the chronic influence of nonphysiologically high glucose concentra-
tions is beta-cell dysfunction. This concept is called glucotoxicity. On the one hand, hypergly-
caemia has an impact on the gene level. For example the transcription of Pdx1, which plays an
important role in terms of insulin promotor regulation, is impaired and islets lose DNA binding
activity of Pdx1 when exposed to high blood glucose levels. As a result, insulin gene expression
is impaired, too. On the other hand, desensitisation of beta-cells to high glucose concentrations
occurs. In contrast to glucose toxicity the cells can recover from desensitisation during which no
insulin secretion is possible due to depletion (Robertson et al., 2003). Moreover, it is suspected
that elevated levels of fatty acids have a similar impact on the beta cells. Although the exact
effects are still not clear, there is evidence that the so-called lipotoxicity also impairs insulin
gene expression as well as secretion and induces beta-cell apoptosis (Robertson et al., 2004).
In conclusion, it was shown that in patients with diabetes type 2 beta-cell volume is reduced by
up to 63 % and beta-cell apoptosis was up to 10-fold higher compared to nondiabetic subjects
(Butler et al., 2003).
1.2.6 Diabetes mellitus and oxidative stress
Other than glucose toxicity and damage by free fatty acids another parameter also plays an
important role in the molecular pathophysiology of diabetes: The noxious effect of reactive
oxygen (ROS) and nitrogen species (RNS), summarised as oxidative stress. This condition
occurs when there is a constant imbalance between the production of free radicals that cause
oxidative damage and cellular antioxidant defence mechanisms (Evans et al., 2003).
On the molecular level, oxidative stress arises from molecules with unpaired electrons. Such
molecules with unpaired electrons are highly reactive and can cause damage to cellular or-
ganelles. Oxidative damage can occur due to heat, ultraviolet and ionising radiation, inflam-
matory cytokines and redox reactions. An important cellular source of ROS and RNS is the
mitochondrial respiratory chain and the redox reactions happening in it. During oxidative phos-
phorylation molecular oxygen is reduced, resulting in a partly conversion to .O2-. Superoxide is
eliminated by the formation of H2O2 by superoxide dismutase 2. Catalase then converts hydro-
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gen peroxide to H2O and O2. However, the highly reactive .OH or other ROS and RNS can also
arise from hydrogen peroxide and thus lead to oxidative stress. The formation of .OH out of
H2O2 has already been described in 1894 by Henry Fenton and is thus called ”Fenton reaction”
(Fenton, 1894; Boveris, 1977). An overview of some reactive species is given in table 1.4.
ROS RNS
.O2- (Superoxide) .NO (Nitric oxide)
.OH (Hydroxyl) .NO2- (Nitrogen dioxide)
.RO2 (Peroxyl)
.HO2- (Hydroperoxyl)
Table 1.4: Examples of reactive species (Evans et al., 2002).
While redox reactions are a physiological and vital part of every cell, the imbalance between
oxygen free radical formation and its elimination via cellular defence mechanisms can cause
oxidative damage to proteins and can change their function. This can trigger stress-sensitive
pathways, among which NF-kappaB, c-Jun N-terminal kinase (JNK) and p38 mitogen-activated
protein. Additionally, lipids and DNA molecules can directly be oxidised and thus get damaged
(Evans et al., 2003).
Consequently, oxidative stress plays an important role in many diseases’ aetiology, including di-
abetes. Besides glucose autoxidation and glycation of proteins, hyperglycaemia increments the
production of ROS in mitochondria (Wolff and Dean, 1987). Furthermore, free fatty acids in-
crease ROS by promoting beta-oxidation and mitochondrial uncoupling (Carlsson et al., 1999).
A good example for the connection between radicals and diabetes is the NF-kappaB-pathway.
It is activated by oxidative stress, hyperglycaemia and elevated free fatty acids (Mohamed et al.,
1999). NF-kappaB is located in the cytoplasm and activated by phosphorylation of its inhibitory
subunit (Karin and Ben-Neriah, 2000). It regulates the expression of several growth and proin-
flammatory factors, for example VEGF, TNF-alpha and IL-1beta. It was found that NF-kappaB
activation correlates with the degree of albuminuria in diabetics (Hofmann et al., 1999).
There is evidence that the formation of ROS is increased and antioxidant defences are reduced
in diabetics and that oxidative stress is a part of the early stages of its pathophysiology. The
oxidative stress is measurable before the disease becomes clinically apparent and related to its
onset (Maxwell et al., 1997; Nourooz-Zadeh et al., 1997). Furthermore, studies found that high
levels of reactive species not only correlate with the development of vascular and neurological
complications and proteinuria, but also with insulin resistance (Yaqoob et al., 1993; Opara et al.,
1999). In conclusion, figure 1.2 summarises the influence of oxidative stress on the pathophys-
iology of diabetes mellitus type 2.
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 Free fatty acids Hyperglycaemia
 Mitochondrial ROS
 Oxidative stress
Macromolecule damage
 Nf-kB
 p38 MAPK
 JNK/SAPK
 Sorbitol  AGE

RAGE
 DAG

 PKC
 Cytokines
 Prostanoids
 
Insulin resistance Beta-cell dysfunction
Diabetic complications
Figure 1.2: The role of oxidative stress in the pathophysiology of diabetes mellitus type 2 (Evans
et al., 2003). Gluco- and lipotoxicity induce oxidative stress and thereby trigger
stress-sensitive pathways. Ultimately, the beta-cell is rendered dysfunctional.
Regarding the cellular level, it has to be taken account of the fact that the beta-cell has a lower
antioxidant defence capacity than other cells. Gene expression of several enzymes, including
superoxide dismutase, catalase and glutathione peroxidase was shown to be markedly lower or
even not detectable in mouse islets in comparison to other tissues (Lenzen et al., 1996). The
physiology of insulin secretion is disrupted by oxidative imbalance in various ways. To begin
with, the amount of GLUT2 (Glucose transporter 2) in the membrane of beta-cells is reduced
in db/db mice and animals stressed with high carbohydrate diet (Thorens et al., 1992; Kluth
et al., 2011). Furthermore, the Krebs cycle is a target for oxidative stress. On the one hand,
its enzymes are directly inhibited by oxidants. H2O2 for example interferes sharply with the
alpha-ketoglutarate dehydrogenase complex (Tretter and Adam-Vizi, 2000). On the other hand,
anaplerosis and cataplerosis are sensitive toward oxidants and their disruption has negative im-
pact on insulin secretion. For instance, suppression of pyruvate carboxylase activity results in a
lack of substrate for the Krebs cycle and thereby adverses insulin secretion (Hasan et al., 2008).
Also, mitochondria themselves are altered in terms of morphology and function, presenting
changes in protein expression and density volume (Anello et al., 2005). Moreover, the ATP-
sensitive potassium channels in the beta-cell’s cell membrane are affected by oxidative stress
directly as well due to hyperpolarisation of the cell membrane (Islam et al., 1993; Krippeit-
Drews et al., 1994). In conclusion, glucose uptake, processing in the Krebs cycle and coupling
between mitochondria and ATP-sensitive potassium channels are influenced by oxidants, ac-
counting for a deteriorated insulin secretion under oxidative stress.
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1.3 Thioredoxin family proteins
In defence against oxidative stress, cells use redox signalling in order to re-establish redox bal-
ance after exposure to reactive species (Dro¨ge, 2002). Very important actors in redox signalling
are thioredoxin (Trx) family proteins. This group of proteins is named after the first discov-
ered thioredoxin. While it has already been found in the year 1964 (Laurent et al., 1964), the
common link between Trx family proteins - their basic three-dimensional structure - was only
described in 1995. It consists of a four-stranded beta-sheet and three encircled alpha-helices
with the motif Cys-x-x-Cys as its active region (Martin, 1995). Among the members of the Trx
family are glutaredoxins (Grx), peroxiredoxins (Prx) and thioredoxins.
1.3.1 The thioredoxin system
In 1964, Trx was discovered as an essential factor for DNA synthesis in E. coli. It acts as an
electron donor for ribonucleotide reductase and is thus a vital part of every organism (Laurent
et al., 1964). Knockout mice in deficiency of TRX1, 2 or the respective reductase are unviable
or die as embryos (Matsui et al., 1996; Nonn et al., 2003; Jakupoglu et al., 2005; Conrad et al.,
2004). Trx features the active site Cys-Gly-Pro-Cys (Holmgren, 1968) which is present in both
major isoforms. Trx1 and TrxR1 are located in the cytoplasm and in the extracellular space
(Rubartelli et al., 1992; So¨derberg et al., 2000). It was also shown that it can move into the
nucleus under certain conditions (Makino et al., 1999). Trx2 and its reductase are found in
the mitochondria. Beyond its important role for DNA synthesis, the Trx system acts as a key
regulator of redox signalling. Its influence on the redox state is gained by a simple dithiol
mechanism. Thioredoxin (Trx-(SH)2) reduces the disulfide in the substrate (P-S2) and is in turn
reduced by thioredoxin reductase (TrxR-(SH)2) which uses NAPDH as electron donor (Figure
1.3) (Holmgren, 1985).
+
NAPDH+H
+
NAPD
TrxR-S
2
TrxR-(SH)
2
Trx-(SH)
2
Trx-S
2
P-S
2
P-(SH)
2
Figure 1.3: The dithiol mechanism of Trx.
Apart from its involvement in maintaining the cellular redox state, Trx is strongly linked to cell
proliferation and apoptosis (Powis and Montfort, 2001). Reduced Trx forms a complex with
ASK1, a MAP kinase. If oxidative stress occurs and Trx becomes oxidised, ASK1 triggers p38
and JNK pathways, inducing apoptosis (Saitoh et al., 1998). Additionally, several transcription
factors are regulated by Trx. An important example is again NF-kappaB, whose DNA binding
activity is altered by the dithiol mechanism. Thus, the expression of proinflammatory genes is
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indirectly controlled by redox signalling (Hayashi et al., 1993).
Other members of the thioredoxin system are thioredoxin-interacting protein (Txnip) and Nu-
cleoredoxin (Nrx).
1.3.2 Peroxiredoxins
Peroxiredoxins reduce hydrogen peroxide, peroxynitrite and organic hydroperoxides. In con-
trast to catalase and glutathione peroxidase, Prx use their redox-active cysteines to achieve this
goal. There are six different Prx which can be categorized according to the number of cysteinyl
residues which take part in their redox reaction. Typical double-cysteine (Prx1 - 4) and atypical
double-cysteine Prx (Prx5) have two cysteines in their active site while Prx6 is categorized as
single-cysteine. The second part of the two-step reducing reaction depends on the number of
available cysteines. Firstly, one active-site cysteine (Cys-SH) is oxidised to cysteine sulfenic
acid (Cys-SOH). In 2-Cys Prx this sulfenic acid forms a disulfide with the second cysteine
(atypical double-cysteine Prx) or a second Prx molecule (typical double-cysteine Prx) and is
then reduced by Trx. Due to the lack of a second cysteine, 1-Cys Prx require GSH for reduction
(Rhee et al., 2001) (Figure 1.4).
H O
2
Prx
SOH
SH
Prx
S
SH
Prx
HS
S
Trx
SH
SH
Prx
SH
SH
+Prx
S
SH
Trx
HS
S
Trx-S
2
Prx-(SH)
2
Prx-(SH)
2
H O
2 2
H O
2
+
a
b
c
d
Figure 1.4: The Prx pathway. a) Detoxification of H2O2, b - d) Restoration of Prx using the
example of a typical double-cysteine Prx.
Due to their function as peroxidase, Prx are important scavengers of cellular H2O2. Thereby,
they also have influence on cell proliferation and apoptosis (Fujii and Ikeda, 2002). Prx can
be found in every cellular compartment and are form around 0.7 % of the soluble protein in
mammalian cells (Seo et al., 2000). Prx1 and 2 are mainly found in the cytoplasm and the nu-
cleus, Prx3 only in the mitochondria, Prx4 in the cytosol and the endoplasmatic reticulum, Prx5
in the cytoplasm, mitochondria and peroxisomes and Prx6 in the cytosol. The consequences
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of Prx deficiency were demonstrated in several models. Prx1 knockout mice have a decreased
lifespan. At about 9 months of age they develop haemolytic anaemia due to raised ROS levels
in erythrocytes. Furthermore, the rate of cancer is increased: Mice suffer from lymphomas,
sarcomas and carcinomas (Neumann et al., 2003). The effects in Prx2 deficient mice are simi-
lar. Anaemia with deformed erythrocytes and elevated ROS levels are present in these animals
(Lee et al., 2003). A recent study suggests that Prx3 knockout mice show adipocyte hypertro-
phy as well as impaired glucose tolerance and insulin resistance (Huh et al., 2012). Moreover,
increased intracellular ROS levels were found (Li et al., 2007). Testicular atrophy is observed
in Prx4 deficient mice (Iuchi et al., 2009) and overexpression of Prx5 was found to inhibit the
p53-dependent generation of ROS and thus to prevent apoptosis (Zhou et al., 2000). Ultimately,
mice lacking Prx6 are characterised by low survival rates and raised protein oxidation (Wang
et al., 2003).
1.3.3 The glutaredoxin system
The glutaredoxin system had been first described in the 1970s as a hydrogen transport system
consisting of NAPDH, glutathione, glutathione reductase and glutaredoxin. It was found to
reduce ribonucleotides and thus to ensure DNA synthesis in an E. coli mutant lacking Trx. In
mammals, there are four glutaredoxins which can be grouped as dithiol Grx with two cysteine
residues in their active site (Grx1 and 2) and monothiol Grx with only one cysteine (Grx3 and
5) (Holmgren, 1976, 1979). By definition, Grx use GSH as substrate. According to the number
of cysteine residues in the active site, two different mechanisms in the Grx reaction can be
differentiated. In the dithiol mechanism, the N-terminal Cys of the active site and its substrate
form a disulfide by nucleophilic substitution. This disulfide is then reduced by the C-terminal
Cys of Grx, resulting in oxidised Grx (Grx-S2) and its reduced substrate (P-(SH)2). Grx then
again is reduced by GSH. In the monothiol mechanism the N-terminal Cys interacts with the
GSH residue of the substrate (P-S-SG) and creates Grx-S-SG which is again reduced by GSH.
Oxidised GSSG then again is reduced by glutathione reductase using NAPDH as electron donor
(Figure 1.5) (Holmgren, 1978; Bushweller et al., 1992).
+
NAPD
+
NAPDH+H
GSSG
2 GSH
Grx-(SH)
2
Grx-S
2
P-S
2
P-(SH)
2
GR
S
SH
GR-S
2
Figure 1.5: The dithiol mechanism of Grx.
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Grx1 with the active site Cys-Pro-Tyr-Cys is mainly located in the cytoplasm, but it was also
found in the nucleus and in the intermembrane space of mitochondria (Lundberg et al., 2004;
Pai et al., 2007). The protein is a major actor in the thiol-disulfide exchange (Holmgren, 1989).
Besides, it was shown that it plays a role in cell differentiation (Takashima et al., 1999) and reg-
ulates several transcription factors among which NF-kappaB, AP-1, CREB and AKT1 (Hirota
et al., 2000; Daily et al., 2001). Thus, it also protects cells from apoptosis (Chrestensen et al.,
2000; Murata et al., 2003). Embryonic fibroblasts of Grx1 deficient mice are more susceptible
to deleterious effects of some chemical agents (Ho et al., 2007).
There are two isoforms of Grx2 of which one (Grx2a) is located in the mitochondria and the
other (Grx2b) was found in the nucleus (Lundberg et al., 2001). Besides, testis- and cancer-
specific isoforms exist (Lo¨nn et al., 2008). Grx2 can be reduced by TrxR and forms an iron-
sulfur cluster which acts as a redox sensor and activates it (Berndt et al., 2007; Lillig et al.,
2005). It regulates the redox state in the mitochondria (Beer et al., 2004) and protects cells
from apoptosis (Enoksson et al., 2005). In Grx2 knockout mice it was shown that a lack of this
protein leads to increased susceptibility to oxidative stress (Wu et al., 2011).
Grx3 resides in the cytosol and the nucleus. Similar to Grx2, it can also form iron-sulfur clusters
(Haunhorst et al., 2010) and is required for the biosynthesis of haem (Haunhorst et al., 2013).
Grx3 inhibits NF-kappaB and JNK pathways and thus apoptosis (Witte et al., 2000). Moreover,
it was found to be a modulator of T cells (Kato et al., 2008). A recent study found that mice
overexpressing Grx3 are protected against cardiac hypertrophy and show enhanced cardiomy-
ocyte contractility (Jeong et al., 2006). In contrast, Grx3 knockout mice are embryonic lethal
(Cha et al., 2008).
Grx5 is required for the assembly of iron-sulfur clusters in the mitochondria. A lack of the pro-
tein thus leads to an accumulation of iron and inactivation of enzymes which require iron-sulfur
clusters (Rodrı´guez-Manzaneque et al., 2002). It is necessary for physiological haem biosyn-
thesis (Ye et al., 2010): Studies show that anaemia and embryonic death is caused by deficiency
of Grx5 in zebrafish (Wingert et al., 2005) and in 2007 a human male lacking Grx5 was reported
to suffer from anaemia (Camaschella et al., 2007).
A summary of the previously discussed Trx family proteins is given in table 1.5.
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1.4 The db/db mouse
The spontaneous mutant strain of obese black mice was firstly described in the year 1966 (Hum-
mel et al., 1966). However, only after 30 years the underlying genetics was identified. A point
mutation in the downstream intron of the transmembrane leptin receptor Ob-Rb gene causes a
splicing mutation and renders those animals unresponsive to leptin (Chen et al., 1996). This
hormone is released by adipocytes und plays a major role in energy homeostasis and eating
behaviour (Friedman and Halaas, 1998). In the hypothalamus it triggers inappetence and thus
eventually loss of weight. Therefore, homozygote mice show unrepressed eating behaviour
leading to obesity and insulin resistance, hyperinsulinaemia, hyperglycaemia, and ultimately
insuffiency of insulin secretion. As a consequence, this strain is used as an animal model for
type 2 diabetes (Coleman, 1978; Tuman and Doisy, 1977).
1.5 Aims of the study
The impact of diabetes starting from its very early stages, via the clinical onset through to the
late complications has been outlined. There is a marked influence on the physiology of the body,
especially on the islets of Langerhans and insulin as their product. Hyperglycaemia, free fatty
acids and oxidative stress play a major role as from the early pathophysiology of the disease.
The imbalance between reactive oxygen and nitrogen species on the one hand, and cellular an-
tioxidant defences on the other hand have become an important focus of research. It has been
shown that reactive molecules are increased in diabetics. Thus, we wanted to study how apop-
tosis of islets and diabetes are connected with defective redox signalling.
In this study homozygote BKS(D)-Leprdb/JOrlRj (db/db) mice were compared with heterozy-
gote BKS(D)-Leprdb/JOrlRj Te´moin (db/+) counterparts in terms of general development and
the changes in the islets of Langerhans. Furthermore, the behaviour of Grx, Prx and Trx in the
islets over time were observed. In detail, the aims of this study were:
• to observe the changes in body weight and blood glucose level with time in db/db mice
and their heterozygote counterparts.
• to qualify and quantify the changes of the islets of Langerhans in terms of morphology,
number and area.
• to study the changes in insulin gene and protein expression.
• to describe proliferation and apoptosis of the beta cells.
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• to qualitatively analyse the proteins of the Grx, Prx and Trx systems in the islets and the
surrounding exocrine tissue.
• to further analyse Grx1 and 5 and their gene and protein expression.
• to detect ROS in isolated islets of db animals.
• to gain insight into the role of leptin by administering of the hormone to MIN6 cells and
analysing the protein levels of insulin, Grx1 and 5.
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2.1 Materials
2.1.1 Instruments
Centrifuge Biofuge 13 Heraeus (Hanau, Germany)
Centrifuge Universal 320R Hettich (Tuttlingen, Germany)
Confocal scanning microscope SP2 AOBS Leica (Bensheim, Germany)
Crysostat CM1850 Leica (Wetzlar, Germany)
Digital microscope camera DFC 420 C Leica (Wetzlar, Germany)
Fluorescence microscope LB30T Leica (Wetzlar, Germany)
Glucometer OneTouch Ultra 2 LifeScan (Neckargemu¨nd, Germany)
Incubator T-6030 Heraeus (Hanau, Germany)
Magnetic stirrer Ikamag RCT Ika (Staufen, Germany)
Microplate Reader Mithra LB940 Berthold (Bad Wildbad, Germany)
Precision scale Sartorius (Go¨ttingen, Germany)
Real-Time PCR System StepOnePlus Applied Biosystems (Darmstadt, Germany)
Shaking Water Bath 1083 GFL (Eppelheim, Germany)
Spectrophotometer NanoDrop 1000 Thermo Scientific (Schwerte, Germany)
Sterile Benches Thermo Scientific (Schwerte, Germany)
Thermal cycler DOPPIO VWR (Darmstadt, Germany)
Vortexer 34524-200 Cenco (Breda, Netherlands)
Vortexer Reax 2000 Heidolph (Schwabach, Germany)
2.1.2 Chemicals
2’,7’-dichlorofluorescein diacetate Sigma (Mu¨nchen, Germany)
5 X First Strand Buffer Invitrogen (Darmstadt, Germany)
Aqua dest. B. Braun (Melsungen, Germany)
beta-mercaptoethanol Life Technologies (Darmstadt, Germany)
BSA, fatty acid free PAA (Co¨lbe, Germany)
Ciprofloxacin Bayer (Leverkusen, Germany)
Collagenase Roche (Mannheim, Germany)
dimethylsulfoxide (DMSO) Sigma (Mu¨nchen, Germany)
DMEM Life Technologies (Darmstadt, Germany)
DNase I Invitrogen (Darmstadt, Germany)
DNase reaction buffer Invitrogen (Darmstadt, Germany)
DTT 0.1 M Invitrogen (Darmstadt, Germany)
dNTPs 10 mM Invitrogen (Darmstadt, Germany)
EDTA 25 mM Invitrogen (Darmstadt, Germany)
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Embedding medium ”Cryoblock” Biosystems (Nunningen, Switzerland)
FBS biowest (Nuaille´, France)
Gentamycin Ratiopharm (Ulm, Germany)
Glucose-40 concentrate Braun (Melsungen, Germany)
Glycerol Merck (Darmstadt, Germany)
Hank’s Salt Solution (10x) Biochrom (Berlin, Germany)
HCl 37 % Sigma (Mu¨nchen, Germany)
Hepes-Buffer (1 M) Biochrom (Berlin, Germany)
Hoechst 33342 Calbiochem (Darmstadt, Germany)
Medium 199 Gibco (Karlsruhe, Germany)
Na2HPO4 Merck (Darmstadt, Germany)
NaH2PO4 Merck (Darmstadt, Germany)
NaCl Roth (Karlsruhe, Germany)
NaCl 0.9 % B. Braun (Melsungen, Germany)
NaOH Merck (Darmstadt, Germany)
NP-40 United States Biological (Swampscott, USA)
Oligo (dT) primers Applied Biosystems (Darmstadt, Germany)
Paraformaldehyde Merck (Darmstadt, Germany)
PBS PAA (Co¨lbe, Germany)
Penicillin-Streptomycin Lonza (Ko¨ln, Germany)
Penicillin-Streptomycin (cell culture) Life Technologies (Darmstadt, Germany)
Picric acid 1.2 % Merck (Darmstadt, Germany)
ProLong Gold Invitrogen (Karlsruhe, Germany)
Protease Inhibitor Cocktail Tablets (Com-
plete, EDTA-free)
Roche (Mannheim, Germany)
Phosphatase Inhibitor Cocktail 3 Sigma (Mu¨nchen, Germany)
Recombinant Mouse Leptin, CF R&D Systems (Wiesbaden, Germany)
RNase-free water Gibco (Darmstadt, Germany)
TNF-alpha (human rec.) Bachen (Bubendorf, Schweiz)
Triton X-100 Merck (Darmstadt, Germany)
TRIS base Merck (Darmstadt, Germany)
TRIS HCl Sigma (Mu¨nchen, Germany)
Trypsin-EDTA Gibco (Darmstadt, Germany)
2.1.3 Solutions
cell lysis buffer 1.25 ml NP-40 buffer (0.8 g NaCl, 10 ml glycerol, 1 ml NP-
40, 2 ml EDTA 100 mM), 50 µl protease inhibitor cocktail
(25 x), 12.5 µl phosphatase inhibitor cocktail 3
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Hank’s solution
(islet isolation)
900 ml a.dest., 100 ml Hank’s salt solution, 35 ml
Hepes-Buffer, 10 ml Ciprofloxacin, 10 ml Penicillin-
Streptomycin, 1 ml Gentamycin
master mix
(cDNA Synthesis)
4 µl 5 X First strand buffer, 2 µl 0.1 M DTT, 1 µl mM
dNTPs, 1 µg µl−1 oligo dTs, 1 µl Superscript III Reverse
Transcriptase
master mix
(qRT-PCR)
10 µl Power SYBR Green PCR Master Mix, 6.4 µl RNase-
free water, 0.6 µl Primer (for + rev 1:1, 1:10 in RNase-free
water)
narcotic agent 1 ml Ketamine 10 %, 0.8 ml Xylazine 2 %, 8.2 ml NaCl
0.9 %;
0.1 ml / 10 g body weight
P/FCS
(islet isolation)
850 ml a. dest., 100 ml Medium 199, 50 ml FBS
TRIS buffer
(immunohistology)
60.5 g TRIS base in 700 ml a. dest., 90 g NaCl
Zamboni 20 mg paraformaldehyde in 150 ml picric acid solution,
heat to 60 ◦C for 2h, neutralise with 2.5 % NaOH, filter;
fill up to 1000 ml with PBS pH 7.3
2.1.4 Kits
Mouse Insulin ELISA Kit DRG Instruments GmbH (Marburg, Germany)
Mouse Grx1 ELISA Kit Wuhan EIAab Science (Wuhan, China)
Mouse Grx5 ELISA Kit CUSABIO Biotech (Wuhan, China)
Power SYBR Green PCR Master Mix Applied Biosystem (Darmstadt, Germany)
RNeasy Plus Micro Kit Qiagen (Du¨sseldorf, Germany)
SuperScript III Reverse Transcriptase Invitrogen (Karlsruhe, Germany)
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2.1.5 Antibodies
Several antibodies for redoxins were manufactured (Hanschmann, 2011) and kindly provided by
the research group of Professor Lillig, Institute of Biochemistry, Ernst-Moritz-Arndt-University,
Greifswald.
Name Source Dilution Origin
beta-tubulin Rabbit 1:10000 Abcam (Cambridge, England)
Insulin Guinea Pig 1:500 Dako (Hamburg, Germany)
Ki-67 Rat 1:100 Dako (Hamburg, Germany)
Caspase-3 Rabbit 1:1600 Cell Signaling (Frankfurt, Germany)
Grx1 Rabbit 1:200 Santa Cruz Biotechnology (USA)
Grx2 Rabbit 1:100 RG Lillig (Greifswald, Germany)
Grx3 Rabbit 1:1000 RG Lillig (Greifswald, Germany)
Grx5 Rabbit 1:1000 RG Lillig (Greifswald, Germany)
Prx1 Rabbit 1:500 RG Lillig (Greifswald, Germany)
Prx2 Rabbit 1:500 RG Lillig (Greifswald, Germany)
Prx3 Rabbit 1:500 RG Lillig (Greifswald, Germany)
Prx4 Rabbit 1:500 Santa Cruz Biotechnology (USA)
Prx5 Rabbit 1:500 RG Lillig (Greifswald, Germany)
Prx6 Rabbit 1:500 RG Lillig (Greifswald, Germany)
Trx1 Rabbit 1:1000 RG Lillig (Greifswald, Germany)
Trx2 Rabbit 1:1000 RG Lillig (Greifswald, Germany)
TrxR1 Rabbit 1:200 RG Lillig (Greifswald, Germany)
TrxR2 Rabbit 1:1000 Santa Cruz Biotechnology (USA)
FITC
(Secondary)
Donkey 1:400 Jackson (Newmarket, England)
Rhodamine Red
(Secondary)
Donkey 1:400 Jackson (Newmarket, England)
Table 2.1: List of antibodies and corresponding dilutions.
2.1.6 Primer sequences for qRT-PCR
Target Sequence (5’ to 3’)
beta-actin fwd GTG GGA ATG GGT CAG AAG G
beta-actin rev GAG GCA TAC AGG GAC AGC A
Ins-1 fwd TAT AAA GCT GGT GGG CAT CC
Ins-1 rev GGG ACC ACA AAG ATG CTG TT
Grx1 fwd GAG CAG TTG GAC GCG CTG G
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Grx1 rev CTC GCC ATT GAG GTA CAC TTG C
Grx2 fwd CTG CTC TTA CTG TTC CAT GGC CAA GAA G
Grx2 rev CAC TGA TGA ACC AGA GGC AGC AAT TTC
Grx5 fwd GAA GAA GGA CAA GGT GGT GGT CTT C
Grx5 rev GCA TCT GCA GAA GAA TGT CAC AGC
Table 2.2: List of primers.
Sequences for Grx1, 2 and 5 were kindly provided by RG Lillig, Greifswald.
2.1.7 Computer based data handling
2.1.7.1 Processing of immunostained tissues
Images were taken with Leica Application Suite (v 3.8.0) using digital microscope camera
DFC 420 C and analysed with ImageJ (Wayne Rasband, National Institutes of Health, USA)
and custom macros.
2.1.7.2 Figures
Data were analysed using Graph Pad Prism 5 (GraphPad Software, San Diego, USA).
2.1.8 Research animals
Male BKS(D)-Leprdb/JOrlRj mice (db/db) and BKS(D)-Leprdb/JOrlRj Te´moin (db/+) mice
aged 5 weeks were bought from Charles River (Sulzfeld, Germany). Animals were housed
according to institutional guidelines (room temperature (22.0±0.5) ◦C, 12 hours light / dark
cycle, 60 % humidity) with tap water and standard diet pellet food (Altromin, Lage, Germany)
ad libitum. Approval of research was obtained under the code GI20/11-Nr.A18/2010 from
institutional ethical committee.
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2.2 Methods
2.2.1 Pancreatectomy and Immunofluorescence
Animals were sedated using Ketamine and Xylazine (section 2.1.3). The abdominal aorta was
cut, the pancreas removed and fixed with Zamboni for four hours. Later the organ was washed
and stored in PBS overnight. On the next day, the buffer was replaced with 10 % sucrose solu-
tion overnight. Ultimately, the pancreas was embedded in cryoblock embedding medium and
frozen at −80 ◦C.
Sections of 6 µm thickness were cut using Leica Crysostat CM1850. Slides were washed with
PBS and blocked with 1 % donkey serum containing 0.3 % Triton X-100 for 20 minutes. For
Ki-67 staining, antigen retrieval was performed with NaOH 0.09 M for three minutes followed
by another wash cycle.
Sections were incubated with primary antibodies diluted in 1 % donkey serum containing 0.01 %
Triton X-100 overnight at 4 ◦C.
After washing thrice to remove the primary antibodies, sections were incubated with solution
containing secondary antibodies in 5 % mouse serum for one hour at room temperature. The
procedure was finished by staining nuclei with Hoechst in 0.1 % TRIS buffer pH 7.6 and the
sections were mounted with a cover slip using ProLong Gold. The antibody dilutions which
were used are listed in table 2.1.
2.2.2 Analysis of images obtained through immunohistology
Immunostained slides were used to analyse mean islet area, to study proliferation and apoptosis
of the beta-cells and mean staining intensity of redoxins and insulin. Samples were entirely
sectioned and two consecutive sections were placed on a slide and regarded as one (results were
divided by two in the analysis). An interval of 140 µm was maintained in order to avoid multiple
inclusion of islets and to be able to assess the whole organ.
The islet area (section 3.3.3) was measured as described before (Kilimnik et al., 2009). Images
of single or multiple islets were taken from slides stained with insulin in order to identify the
islets. ImageJ was calibrated to match their scale and the mean islet area was obtained.
Nuclei stained with Ki-67 (section 3.4.1) were counted manually and caspase-3 (section 3.4.2)
was analysed qualitatively.
Intensity measurements in immunostained tissue were done in order to semiquantitatively anal-
yse protein levels. For obtaining the mean staining intensity of insulin (section 3.3.4) Grx1 and
5 (sections 3.6.1.2 and 3.6.2.2) in pancreatic tissue samples were prepared simultaneously in
batches using the same solutions. Again, a double stain with insulin was performed in order
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to identify islets. Gray scaled pictures were taken under the same conditions and normalised
by removing the background using slides without primary antibodies. The mean grey value in
islets was now obtained using ImageJ. For reasons of better presentability the second highest
measured intensity of every protein which was analysed was respectively set as 100 %.
2.2.3 Islet Isolation
Islet isolation was done according to the protocol established in our group (Lai et al., 2005).
Briefly, mice were anaesthesised by intraperitoneal injection of narcotic agent containing Ke-
tamine and Xylazine (section 2.1.3). The abdominal wall was excised to expose the aorta which
was cut to drain the blood. The pancreas was removed and perfused with 4 mg collagenase dis-
solved in 4 ml Hanks solution through the ductus pancreaticus. For better digestion the organ
was mechanically chopped with a pair of scissors before 10 minutes of incubation in collage-
nase solution at 37 ◦C in a shaking water bath. The sample was vortexed for 10 seconds after
every three minutes of digestion. Finally, the digested tissue was shaken by hand for two min-
utes and the digestion process was eventually stopped by placing the tube containing the tissue
on ice and adding cold Hanks solution. The tube was centrifuged for 3 minutes at 1500 RPM
and the supernatant was discarded. The pellet was dissolved in P/FCS at room temperature and
the islets were hand-picked under stereomicroscope. To overcome the isolation stress, islets
were incubated overnight at 37 ◦C.
2.2.4 Gene expression analysis
2.2.4.1 RNA isolation
RNA was isolated from islets using RNeasy Plus Micro Kit (Qiagen) as per manufacturer’s
instructions. Concentration and quality of the RNA was measured using NanoDrop 1000 Spec-
tophotometer.
2.2.4.2 cDNA Synthesis
cDNA was synthesised using 1 µg of RNA. Solution containing 1 µg of RNA was added to
RNase-free water to a total of 8 µl in a PCR tube. Then 1 µl of DNase I and 1 µl 10 X DNase
reaction buffer were added to obtain 10 µl of reaction mixture. The reaction mixture was incu-
bated for 15 minutes at 37 ◦C to digest the DNA.
The DNase digestion was stopped by adding 1 µl of EDTA. DNA digested RNA was then pre-
incubated at 65 ◦C for 15 minutes to remove the secondary structure and cooled to 4 ◦C for 5
minutes.
To this mixture 9 µl of master mix were added. The resulting 20 µl solution was subjected to a
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thermal cycler programme which involved incubation for 50 minutes at 50 ◦C followed by 15
minutes at 72 ◦C. The resulting cDNA was diluted 1:10 with RNase-free water and used for
qRT-PCR (table 2.3).
x µl solution containing 1 µg of RNA
+ (8− x) µl RNase-free water
= 8 µl solution
DNase digestion + 1 µl DNase I
+ 1 µl 10 X DNase reaction buffer
= 10 µl solution
First incubation:
15 min, 37 ◦C
preincubation + 1 µl EDTA
= 11 µl solution
Second incubation:
15 min, 65 ◦C
5 min, 4 ◦C
cDNA synthesis + 9 µl master mix
= 20 µl solution
Third incubation:
50 min, 50 ◦C
15 min, 72 ◦C
Table 2.3: The procedure of cDNA synthesis.
2.2.4.3 Quantitative Real-Time PCR
Real-Time PCR System StepOnePlus (Applied Biosystems) was used for gene expression anal-
ysis. To 3 µl cDNA (1:10 diluted) 17 µl of master mix containing the respective primers were
added to achieve a total volume of 20 µl per well. Respectively, 3 µl of RNase-free water were
used as negative control.
The process of amplification was started by activating the enzyme at 95 ◦C for 10 minutes fol-
lowed by 40 cycles of denaturation and annealing.
Melting curve analysis was performed for each run (table 2.4).
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step repeats temperature duration
amplification activation 1 95 ◦C 10 min
denaturation 40 95 ◦C 10 s
annealing, extension 60 ◦C 1 min
melting curves denaturation 1 95 ◦C 15 s
melting 40 60 ◦C 1 min
Table 2.4: The procedure of qRT-PCR.
The normalisation of the target genes’ ct values was done with the reference gene using the
formula x = 2ctreference−cttarget .
2.2.5 Cell culture
High passage (passage 70 to 80) mouse insulinoma cells, 6th subclone (MIN6 cells) were cul-
tured in Dulbecco’s Modified Eagle Medium (DMEM) along with 1 % Penicillin / Strepto-
mycin, 20 % FBS and 0.1 % beta-mercaptoethanol at 37 ◦C and 5 % CO2.
Cell splitting was carried out by trypsinisation. Washing was done with PBS before adding
0.5 % Trypsin-EDTA solution. Detached cells were diluted with DMEM, centrifuged for 4
minutes at 1200 RPM and seeded into new flasks.
Prior to analysis leptin was applied for two hours. Leptin was pre-diluted to 0.1 % in 20 mM
TRIS-HCl, pH 8.0. Concentrations of 0 ng ml−1, 0.075 ng ml−1, 0.45 ng ml−1 and 2 ng ml−1 were
applied.
For hypoxia treatment, the respective cells were exposed to an atmosphere consisting of 2 %
O2, 5 % CO2 and 93 % N2 after application of leptin.
Cells were lysed for Grx1 and 5 ELISA and their supernatant was collected for insulin ELISA.
2.2.6 Protein analysis
Protein expression for insulin was measured in MIN6 cell supernatant, protein expression for
Grx1 and 5 in MIN6 cell lysates. Prior to lysis, 1 ml supernatant was extracted before cells
were washed in icecold PBS. 200 µl cell lysis buffer (section 2.1.3) were added. Cells were
transferred into a tube and incubated on ice for 20 minutes. Supernatant was gathered by cen-
trifugation for 20 minutes at 12000 RPM. Insulin, Grx1 and 5 were analysed using ELISA
technique.
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2.2.6.1 Insulin ELISA
Insulin content of MIN6 cell supernatant was analysed using a mouse insulin ELISA kit (DRG)
as per manufacturer’s instructions.
2.2.6.2 Grx1 and 5 ELISA
Grx1 content of MIN6 cell lysate was analysed using a mouse Grx1 ELISA kit (EIAab) and
Grx5 content using a mouse Grx5 ELISA kit (CUSABIO) as per manufacturer’s instructions.
2.2.7 ROS detection
2,7-dichlorofluorescein diacetate (DCFH-DA) indicator dye was used for detection of intracel-
lular reactive oxygen species production level in isolated islets. Islet cells of 24 weeks old ani-
mals were isolated and three groups were formed including an untreated control, high glucose
treated (20 mM for 2 hours), and TNF-alpha treated (1 µM for 15 minutes). Samples were incu-
bated in serum-free medium containing 10 µM DCFH-DA indicator dye dissolved in dimethyl-
sulfoxide (DMSO) for 30 minutes at 37 ◦C in the dark. Afterwards, samples were rinsed with
pre-warmed serum-free medium and immediately analysed with a confocal microscope. DCF
fluorescence was measured in 3600 µm2 regions of interest and corrected for background flu-
orescence. The 488 nm band of the argon ion laser of the confocal laser scanning microscope
was used for fluorescence excitation and the emission was recorded using a longpass LP 515 nm
filter set. Fluorescence intensities were quantified using Leica Simulator software and images
taken of the respective region of interests. Access to his research group’s confocal microscope
was kindly granted by Prof. Dr. Heinrich Sauer and guidance was provided by Dr. Fatemeh
Sharifpanah (Department of Physiology, Justus-Liebig-University, Gießen).
2.2.8 Statistics
Statistics were performed with GraphPad Prism 5 using Mann Whitney test, one-way and two-
way ANOVA as appropriate. Results contain mean values± SEM and a p value<0.05 was con-
sidered to be statistically significant. Significance levels were labelled as follows: *: p<0.05,
**: p<0.005, ***: p<0.0001.
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3.1 General procedure
40 db/db mice and an equal number of db/+ mice were obtained at the age of 5 weeks and
observed from age 6 to 18 weeks. Fasting blood glucose levels and body weight were measured
weekly. Blood glucose was measured using a glucometer after overnight fasting. At the age of
6, 12 and 18 weeks mice were sacrificed for islet isolation and organ harvesting. In each group 3
pancreata were harvested for sectioning and immunohistological analysis whereas islets from 4
to 6 animals were used for RNA extraction and qRT-PCR. The number of sacrificed mice varied
depending on the yield of collected islets. It was estimated that 800 islets would give sufficient
RNA.
3.2 Vital parameters show significant differences
The physical appearance varied between both groups of animals (figure 3.1).
(a) db animals, 6 weeks (b) db animals, 18 weeks
Figure 3.1: Images of db/db and db/+ mice at the age of 6 (a) and 18 weeks (b). Bars indicate
5 cm. Homozygote mice are on the left side of each image.
Homozygote animals gained weight much faster than heterozygotes. At the age of 6 weeks ho-
mozygotes weighed 27.4 g on average, whereas mean weight of their heterozygote counterparts
was 18.9 g, corresponding to a 1.5-fold higher body weight. This difference was 2-fold in 12
week old animals (48.1 g and 23.9 g). At the end of the observation period there was a 2.2-fold
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difference in the mean body weight between db/db (56.9 g) and db/+ mice (26.2 g). In other
words, the mean body weight of db/db mice doubled whereas we only found a 40 % increase
in db/+ animals. Body weight was significantly different (p<0.0001) between db/db and db/+
mice and between 6, 12 and 18 weeks old db/db animals (figure 3.2). The complete follow-up
of the body weight is shown in the appendix (figure 11.1).
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Figure 3.2: Body weight comparison between db/db and db/+ mice. Significant (p<0.0001) dif-
ferences were found between homozygotes and heterozygotes (a) as well as between
homozygotes of different age (p<0.0001) (b) (n = 11 to 40 per time point).
Furthermore, fasting blood glucose levels were significantly different (p<0.0001) between both
groups of animals and between 6 and 18 weeks old db/db mice. The mean value for db/db
mice was higher than that of the db/+ group in all measurements and it tended to increase
during the observation time. In db/db mice it exceeded 200 mg dl−1 on average from 13 weeks
of age onwards whereas heterozygote mice fluctuated between 60.5 mg dl−1 and 106.7 mg dl−1
(figure 3.3). The complete follow-up of the blood glucose level is shown in the appendix (figure
11.2).
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Figure 3.3: Blood glucose comparison between db/db and db/+ mice. db/db mice had distinc-
tively (p<0.0001) higher blood glucose levels than db/+ animals (a). Also, a signif-
icant elevation was found in ageing homozygotes (p<0.0001) (b) (n = 11 to 36 per
time point).
Homozygote mice were defined as diabetic if their blood glucose level exceeded the fourfold
mean deviation of the heterozygotes two weeks in a row. The threshold was 181.22 mg dl−1.
According to this criterion 49 % of the db/db mice became diabetic. The threshold was exceeded
on average from 13 weeks onwards.
3.3 Islet shape and insulin expression
Islets shape was also observed during the study period. Besides observing their number in
the harvested pancreata during isolation, insulin was stained using immunohistology in order
to evaluate islet morphology and to measure mean islet area. By the same method, intensity
of insulin staining was analysed. The expression of the INS-1 gene was also measured using
qRT-PCR.
3.3.1 Changes in number of islets
Islets were counted during the process of isolation and an increased number of islets in homozy-
gote mice at the indicated time points was found. Both groups of animals showed a decrease in
the number of islets at 12 weeks of age, before rising again up to the age of 18 weeks. However,
this effect was less pronounced in heterozygote animals. The average islet count in db/db mice
dropped from 310 at 6 weeks to 169 at 12 weeks and raised again to 245 at 18 weeks, while we
found a mean number of 182, 160 and 214 in db/+ animals. At 6 weeks the islet number was
significantly (p<0.0001) different between both groups of mice. Also the average islet count of
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both groups was statistically significant (p<0.05) in comparison (figure 3.4).
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Figure 3.4: Islet count comparison between db/db and db/+ mice. Homozygotes held more
islets at all time points (a). At 6 weeks (p<0.0001) (a) and on average (p<0.05), the
difference was significant (b) (n = 4 to 6 per time point).
3.3.2 Difference in morphology of pancreatic islets
We confirmed changes in morphology of islets in the db/db mouse that had already been de-
scribed before (Yamazaki et al., 2009). Aging animals had a higher number of small, segmented
and irregular shaped islets and also an increase in the number of larger islets (figure 3.5).
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(a) 6 weeks, db/db, 200x (b) 6 weeks, db/+, 200x
(c) 12 weeks, db/db, 100x (d) 12 weeks, db/+, 200x
(e) 18 weeks, db/db, 200x (f) 18 weeks, db/+, 200x
Figure 3.5: Representative images of the morphology of islets in db/db and db/+ mice (green:
insulin, blue: nuclei; bars indicate 100 µm). At the age of 6 weeks islets of homozy-
gotes were already enlarged but shaped normally (a). Larger islets in 12 weeks
old db/db mice, resulting in huge islet formations (c). As the animals grew older,
small abnormally shaped islets increased in number (e). The changes in the islets of
heterozygotes were more moderate (b), (d), (f).
30
3 Results
3.3.3 Mean area of islet sections was higher in db/db mice
The average area of islets was larger in homozygote mice at all times compared to their het-
erozygote counterparts. An increased mean islet area could be already found in 6 weeks old
animals (0.73 mm2). At the age of 12 weeks a maximum was reached (2.02 mm2) before the
mean islet area dropped again to 1.25 mm2 at 18 weeks of age. On the other hand, heterozygote
animals showed only a moderate increase in islet area. We observed mean values of 0.49 mm2
at both 6 and 12 weeks and eventually 0.66 mm2 at 18 weeks.
The distinction between both groups was significant with p<0.0001 at 12 weeks and with
p<0.005 on average (figure 3.6).
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Figure 3.6: Mean islet area comparison between db/db and db/+ islets. Homozygotes had a
higher mean islet area at all time points (a). At 12 weeks (p<0.0001) (a) and on
average (p<0.005), the difference was significant (b) (n = 3 per time point).
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3.3.4 Insulin staining intensity
The intensity of insulin staining was evaluated using ImageJ. The staining intensity was signif-
icantly higher in db/+ mice with p<0.0001 (figure 3.7).
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Figure 3.7: Staining intensity of insulin. Analysis detected a significantly (p<0.0001) higher
staining intensity for heterozygote islets (n = 9).
3.3.5 Expression of the INS-1 gene in homozygotes and heterozygotes
We measured the gene expression of insulin using qRT-PCR to see whether the expression
varied between both groups. The insulin gene expression over time showed a similar trend in
homozygote and heterozygote mice. We detected a significant (p<0.0001) reduction in insulin
expression in both animal groups with time. When 12 weeks old db/db mice were compared
with 18 week old mice, a 50-fold reduction in INS-1 expression was observed. When 6 weeks
old animals were compared with their 18 weeks old counterparts a 70-fold increased insulin
expression was detected (figure 3.8a). For heterozygote mice those factors were only 3.4 and
2.4 (figure 3.8b).
A significant (p<0.005 at 6 and 12 weeks, p<0.0001 at 18 weeks) decrease in the homozygote
mice’ insulin expression of islets was observed when compared to heterozygote animals. At
6 and 12 weeks, heterozygote mice showed a 2-fold higher expression of insulin than their
homozygote counterparts. At 18 weeks, a 44.5-fold higher insulin expression was found in
heterozygote mice when compared to homozygotes (figure 3.8c).
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Figure 3.8: Gene expression of INS-1. The expression in db/db islets revealed a signifi-
cant (p<0.0001) decrease over time (a), which was also present in in db/+ islets
(p<0.0001) (b). In direct comparison, heterozygotes featured higher expression at
all time points (p<0.005 and p<0.0001) (c) (relative insulin expression normalised
with beta-actin, n = 4 to 6 per time point).
3.4 Changes in the cell cycle
Since islets showed significant variation in size between homozygote and heterozygote mice we
studied the proliferation and apoptosis behaviour of beta-cells from both groups.
In order to gain insight into the proliferation rate of the islets of Langerhans we used Ki-67
as a proliferation marker. Respectively, activated caspase-3 was chosen in order to study pro-
grammed cell death.
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3.4.1 Proliferation plays a major role in islet appearance
The rate of beta-cell proliferation was determined by using an antibody against Ki-67 and in-
sulin was used to clearly identify the beta-cells (figure 3.9).
Figure 3.9: Representative image of Ki-67 staining (green: insulin, red: Ki-67, blue: nuclei,
400x, 12 weeks old db/db mouse). Arrows indicate stained nuclei.
The total amount of stained nuclei was manually counted and the number of proliferating cells
per islet calculated.
The number of Ki-67 positive cells per islet was significantly (p<0.005) higher for homozygote
mice at 12 weeks and on average. We found a mean of 0.5 positive cells for 6 week old animals,
reaching a maximum of 1.3 at 12 weeks before dropping to 0.4 at the age of 18 weeks. The
average values of our heterozygote mice dropped from 0.25 over 0.2 to 0.1 (figure 3.10).
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Figure 3.10: Beta-cell proliferation. Homozygotes featured augmented beta-cell proliferation
at all time points (a). At 12 weeks (p<0.005) (a) and on average (p<0.005), the
difference was significant (b) (n = 3 per time point).
3.4.2 Islets of homozygote mice showed a higher rate of apoptosis
Activated caspase-3 is an early marker for apoptosis which was used to analyse the manifes-
tation of regulated cell death. At the age of 6 and 12 weeks islets of homozygote animals
generally showed more caspase-3 positive cells than those of their heterozygote counterparts.
At the age of 18 weeks this trend was not observed (Figure 3.11).
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(a) 6 weeks, db/db (b) 6 weeks, db/+
(c) 12 weeks, db/db (d) 12 weeks, db/+
(e) 18 weeks, db/db (f) 18 weeks, db/+
Figure 3.11: Representative images of caspase-3 staining (green: caspase-3, red: insulin, blue:
nuclei, 200x).
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In general, caspase-3 staining was located mainly in the islets’ periphery and did not match
insulin staining (Figure 3.12).
(a) (b) (c)
Figure 3.12: Caspase-3 staining, close-up view (green: caspase-3, red: insulin, blue: nuclei).
The area stained with caspase-3 shows no insulin staining. a) nuclei and caspase-3
overlay, b) nuclei and insulin overlay, c) nuclei, caspase-3 and insulin overlay.
3.5 Qualitative analysis of Trx family proteins
In the second part we studied Trx family proteins. The expression of the Grx system, Peroxire-
doxins and the Trx system was analysed using immunohistochemistry. We compared sections
from both groups of mice in order to find out whether there is any expression detected and if so,
whether a difference between both groups could be seen. Sections from mice aged 12 weeks
were chosen due to the huge intergroup difference in islet area and proliferation rate. Images
were transformed to black and white for better contrast.
3.5.1 The Grx system
All of the four Grx proteins were detected in the endocrine and the exocrine tissue of both groups
of mice. However, the staining intensity and stained area varied considerably. In general, we
found a higher signal in db/+ mice for all glutaredoxins.
Grx1 and 5 showed the most marked staining in islets of all redoxins. Also the distinction
between both groups of animals was most pronounced for both proteins. Differences for Grx2
and 3 were less visible, Grx3 being the redoxin with the lowest expression (figure 3.13).
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(a) Grx1, db/db (b) Grx1, db/+
(c) Grx2, db/db (d) Grx2, db/+
(e) Grx3, db/db (f) Grx3, db/+
(g) Grx5, db/db (h) Grx5, db/+
Figure 3.13: Qualitative comparison of the Grx system, 200x, yellow circles indicate islets.
3.5.2 Peroxiredoxins
The expression pattern of the peroxiredoxins was found to be inhomogeneous and scarce ex-
cept for Prx6. While there was basically no expression of Prx1, the behaviour of Prx2 and 3
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resembled the glutaredoxins. Both proteins were expressed higher in db/+ mice. Ultimately,
Prx4 and 5 were expressed similarly in both groups of mice. However, in the exocrine tissue
staining seemed to be higher in db/+ animals. A stronger staining without a visible difference
between both groups was detected for Prx6 (figure 3.14).
(a) Prx1, db/db (b) Prx1, db/+
(c) Prx2, db/db (d) Prx2, db/+
(e) Prx3, db/db (f) Prx3, db/+
(g) Prx4, db/db (h) Prx4, db/+
39
3 Results
(i) Prx5, db/db (j) Prx5, db/+
(k) Prx6, db/db (l) Prx6, db/+
Figure 3.14: Qualitative comparison of the Prx system, 200x, yellow circles indicate islets.
3.5.3 The Trx system
A visible difference between homozygote and heterozygote animals could not be found for both
thioredoxins. In general, staining of Trx1 could be found extensively in both the endocrine and
exocrine pancreas. The same applied for thioredoxin 1 as compared to thioredoxin 2 reductase
(figure 3.15).
(a) Trx1, db/db (b) Trx1, db/+
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(c) TrxR1, db/db (d) TrxR1, db/+
(e) Trx2, db/db (f) Trx2, db/+
(g) TrxR2, db/db (h) TrxR2, db/+
Figure 3.15: Qualitative comparison of the Trx system, 200x, yellow circles indicate islets.
3.6 Analysis of glutaredoxin 1 and 5 expression
To conclude the study of redoxins, we analysed the properties of the glutaredoxin isoforms 1
and 5. Both proteins featured the most evident expression in pancreatic islets in immunohisto-
logical staining and also a strong difference between db/db and db/+ islets (section 3.5). Gene
expression was quantified by running qRT-PCR and protein expression by immunohistochem-
istry.
41
3 Results
3.6.1 Grx1
3.6.1.1 qRT-PCR
The expression of Grx1 was significantly higher (p<0.0001) in heterozygote compared to ho-
mozygote mice at 6 and 12 weeks. The difference between 6, 12 and 18 week old db/db animals
was also significant (p<0.005 for 6 and 12 as well as 6 and 18 weeks, p<0.0001 for 12 and 18
weeks). Heterozygotes showed a higher expression at all time points, while homozygotes pre-
sented huge variations over time. As displayed in figure 3.16a we found a lower expression
at the age of 12 weeks for the latter group. At 6 weeks the expression was on average around
1.9-fold and at 18 weeks around 2.9-fold higher than at the second time point (12 weeks). By
contrast, there was a non-significant decrease in the expression of Grx1 in db/+ animals (figure
3.16b). We compared the expression separately for each time point and found a 3.3, 5.2 and
1.5-fold higher value for db/+ animals (figure 3.16c).
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Figure 3.16: Gene expression of Grx1. The expression in db/db animals showed a signifi-
cant (p<0.005 and p<0.0001) gap at 12 weeks (a), a constant decrease in their
db/+ counterparts (b) and a significantly higher expression (p<0.0001) at 6 and 12
weeks in direct comparison per time point (c) (relative Grx1 expression normalised
with beta-actin, n = 4 to 6 per time point).
3.6.1.2 Staining
The analysis of immunostained tissue confirmed the previously described alterations on the
gene level. In figure 3.17 examples of both groups of animal at all three time points are shown.
Staining was more dense and intense in db/+ mice. Also, a very faint and scarce staining in 12
week old db/db mice is apparent.
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(a) 6 wks, db/db (b) 6 wks, db/+
(c) 12 wks, db/db (d) 12 wks, db/+
(e) 18 wks, db/db (f) 18 wks, db/+
Figure 3.17: Representative images of Grx1 staining (green: Grx1, red: insulin, 400x).
Furthermore, mean intensity of all stained slides was analysed and found to be significantly
(p<0.0001) higher in heterozygote mice compared to homozygotes (figure 3.18).
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Figure 3.18: Staining intensity of Grx1. Analysis detected a significantly (p<0.0001) higher
staining intensity for heterozygote islets (n = 9).
3.6.2 Grx5
3.6.2.1 qRT-PCR
The results of the PCR showed a decrease in the expression of Grx5 in homozygote and het-
erozygote animals with time. The expression was 10.4 (6 weeks) and 5.4-fold (12 weeks) higher
in db/db mice compared to 18 weeks old animals (figure 3.19a). A larger decrease in expression
was found for db/+ mice when compared to db/db animals. In heterozygote mice the expression
was 22.6 (6 weeks) and 7.6-fold (12 weeks) higher compared with 18 week old animals (figure
3.19b). In both groups the decrease in expression was significant with p<0.0001. Also the
difference in Grx5 expression between homozygotes and heterozygotes at 6 and 12 weeks was
significant (p<0.0001) with a mean factor of 2.6 and 1.6. At the age of 18 weeks the difference
in expression became negligible (3.19c).
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Figure 3.19: Gene expression of Grx5. Expression in homozygotes (a) and heterozygotes (b)
followed a significant downward trend (p<0.0001). Direct comparison revealed a
significantly (p<0.0001) higher expression in 6 and 12 weeks old db/+ islets (c)
(relative Grx5 expression normalised with beta-actin, n = 4 to 6 per time point).
3.6.2.2 Staining
We immunostained pancreatic tissue for Grx5. A stronger staining was found in db/+ mice
at the age of 6 and 12 weeks when compared to the homozygotes. At 18 weeks of age the
expression of Grx5 in both groups was similar (figure 3.17).
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(a) 6 wks, db/db (b) 6 wks, db/+
(c) 12 wks, db/db (d) 12 wks, db/+
(e) 18 wks, db/db (f) 18 wks, db/+
Figure 3.20: Representative images of Grx5 staining (green: Grx5, red: insulin, 200x).
Also, the staining intensity of Grx5 was compared using images taken from immunostained
slides. The expression of Grx5 was significantly (p<0.0001) higher in db/+ mice compared to
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db/db animals (figure 3.21).
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Figure 3.21: Staining intensity of Grx5. Analysis detected a significantly (p<0.0001) higher
staining intensity for heterozygote islets (n = 9 per time point).
3.7 Marked differences in cellular ROS production
In an effort to further apprehend the pathophysiology of the islets of Langerhans in db mice,
and to conclude our previous results, we aimed to detect ROS in isolated islets. Harvested islets
were grouped according to the treatment which they received. Control islets underwent no spe-
cial treatment. In order to observe the impact of glucose- and TNF-alpha-induced stress, two
groups were exposed to a high concentration of glucose (20 mM for 2 hours) and TNF-alpha
(1 µM for 15 minutes), respectively (section 2.2.7).
Already unstimulated homozygote islets turned out to exhibit significantly higher ROS produc-
tion than their heterozygote counterparts (p<0.0001). Islets treated with glucose or TNF-alpha
responded in the same way (figure 3.22a). Furthermore, both kinds of islets underwent a dis-
tinctive increase (p<0.0001) in ROS when stimulated by glucose and TNF-alpha. This increase
in reactive species was most notable in db/db islets, while it was less pronounced in islets of
db/+ animals (figure 3.22b, c).
Examples of images used for ROS measurements are displayed in figure 3.23.
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Figure 3.22: Basal ROS production and the influence of glucose- and TNF-alpha-induced stress
on ROS production in db/db and db/+ islets. ROS production was significantly
higher in homozygotes under all conditions (p<0.0001) (a). Both groups featured
an increase in ROS production when stimulated conditions were compared to con-
trols (p<0.0001), although homozygote islets underwent a more pronounced rise
than heterozygote ones (b, c) (n = 54 to 139).
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(a) db/db, control (b) db/+, control
(c) db/db, glucose (d) db/+, glucose
(e) db/db, tnf-alpha (f) db/+, tnf-alpha
Figure 3.23: Representative images of ROS measurements. Left column: db/db islets, right
column: db/+ islets. First row: control islets, second row: glucose treated islets,
third row: TNF-alpha treated islets.
50
3 Results
3.8 The influence of leptin on MIN6 protein expression
MIN6 cells were exposed to four different concentrations of leptin (0 ng ml−1, 0.075 ng ml−1,
0.45 ng ml−1 and 2 ng ml−1) for two hours during cell culture prior to cell lysis as described ear-
lier (section 2.2.5). MIN6 cells were either subjected to normal or hypoxic conditions, because
2 % hypoxia induces the emergence of ROS in pancreatic beta cells.
Insulin content was analysed by ELISA in supernatant. No significant difference in the amount
of secreted insulin in dependence with different leptin concentrations could be detected (figure
3.24a). However, significant differences (p<0.0001 and p<0.005) were found when supernatant
of MIN6 cells which had been cultivated under standard conditions were compared with ones
which had been exposed to hypoxia (figure 3.24b).
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Figure 3.24: Leptin effect and insulin synthesis of MIN6 cells. Insulin content did not differ
significantly between different concentrations of leptin (a) (n = 6 runs per concen-
tration). Significantly higher insulin secretion could be detected for MIN6 cells
which had been cultivated under normoxia in comparison to ones which had been
exposed to hypoxia (p<0.0001 and p<0.005). Leptin concentrations were pooled.
(b) (N = normoxia, H = hypoxia; n = 3 to 24 runs per oxygen level).
Grx1 and 5 contents in MIN6 cell lysates were analysed by ELISA. As for insulin, no signifi-
cant difference was found in Redoxin content for different concentrations of leptin. However,
markedly higher protein levels were detected for Grx5 than for Grx1 (figure 3.25).
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Figure 3.25: Grx 1 and 5 protein concentration at different leptin concentrations. No significant
difference was detected between Grx1 (a) and 5 (b) levels for different concentra-
tions of leptin (n = 5 runs per concentration).
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3.9 Summary of results
Comparison between db/db and db/+ mice
Body weight [g] ***
Blood glucose [mg dl−1] ***
Islet number *
Islet area [mm2] **
qRT-PCR INS-1 ** / ***
(6, 12 / 18 wks)
Intensity Insulin ***
Beta-cell proliferation **
qRT-PCR Grx1 ***
(6, 12 wks)
Intensity Grx1 ***
qRT-PCR Grx5 ***
(6, 12 weeks)
Intensity Grx5 ***
ROS basal rate ***
ROS glucose-stimulated ***
ROS TNF-alpha-stimulated ***
Comparison between leptin concentrations (MIN6)
Insulin ELISA no significance
Grx1 ELISA no significance
Grx5 ELISA no significance
Comparison between normoxia and hypoxia (MIN6)
Insulin ELISA ** / ***
(- leptin / + leptin)
Table 3.1: Summary of the collected results and their significance.
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The various functions of Trx family proteins and their significance in the pathophysiology of
diseases has been a subject of research for the past years. It is suspected that they play an impor-
tant role in the early preclinical stages of diabetes mellitus type 2. Therefore, we explored and
compared the expression of glutaredoxins, peroxiredoxins and thioredoxins in obese, diabetic
db/db and lean, non-diabetic db/+ mice. Despite marked islet hyperplasia and a new genera-
tion of islets, homozygotes lost blood glucose control as the insulin expression in their islets
decreased distinctively over time. Visible differences in the expression patterns of Trx family
proteins were demonstrated. A clear distinction between both groups of mice is marked by the
expression of glutaredoxins 1 and 5. Thus, we believe that there is a strong correlation between
them and the development and progress of the pathological changes in diabetes mellitus type 2
in our research animals.
4.1 The influence of the obese phenotype on the islets of Langer-
hans
There are several animal models for diabetes. We were interested in the consequences of the
obese phenotype on pancreatic islets in contrast to the lean one. Two commonly used types
of mice on the C57BL/6 background are db/db and ob/ob animals, which both have a defec-
tive leptin signalling resulting in obesity. Leptin-deficient ob/ob mice hold a mutation in the
hormone itself. C57BL/6 wild type ob/ob animals develop diabetes but regain blood glucose
control after stages of hyperglycaemia and hyperinsulinaemia (Bell and Hye, 1983). For this
reason, we decided to use db/db mice for our study. The BKS(D)-Leprdb/JOrlRj strain which
we utilised originates from a mixture of the C57BL/KsJ (diabetes susceptible) substrain and
C57BL/6 wild type mice (Hummel et al., 1972; Coleman, 1978). The development of both sep-
arate strains was described recently, showing significant differences between homozygotes and
heterozygotes, respectively, in terms of body weight, blood glucose, plasma insulin, beta-cell
mass, beta-cell proliferation and apoptosis. (Puff et al., 2011).
Accordingly, we observed that obese homozygote db/db mice lost blood glucose control (figure
3.3) while gaining weight rapidly. Both, fasting blood glucose level as well as body weight
(figure 3.2) marked a significant difference between them and heterozygotes. In contrast, those
heterozygotes resembled wild type C57BL/6 mice in body weight and blood glucose levels
which makes them a reasonable control group (data shown in appendix, figure 11.3 and 11.4).
In this way we had the opportunity to study viable homozygote genotypes for 18 weeks and
compare them to their heterozygote counterparts.
As a correlate of raising blood glucose levels we found a strong decrease in the INS-1 gene
expression in homozygotes (figure 3.8) together with less insulin staining in islets (figure 3.7).
54
4 Discussion
In contrast, heterozygotes only presented a slight decrease in insulin gene expression, matching
their stable fasting blood glucose. We neither determined their plasma insulin level nor their
glycated haemoglobin. However, it was shown that insulin levels were dropping and the HbA1c
was rising significantly over time in db/db animals (Yamazaki et al., 2009). Furthermore, pan-
creas weight and pancreatic insulin levels were found to be considerably different when db/db
and heterozygote control animals were compared (Garris and Garris, 2004).
In compensatory response to declining insulin secretion and raising blood glucose levels, there
were considerable cellular changes in the pancreas of our db/db animals. Mean islet area (figure
3.6), islet proliferation (figure 3.10) and islet count (figure 3.4) revealed significant differences
between both groups of animals, which was consistent with the previously described studies
(Puff et al., 2011; Kawasaki et al., 2005). Elevated blood glucose levels may explain these find-
ings, since it was reported that glucose promotes proliferation in several cell lines (Hu¨gl et al.,
1998), in beta-cells of rodents (Swenne, 1982) and humans (Tyrberg et al., 1996), and also in a
rat model of diet-induced diabetes (Del Zotto et al., 2002).
Concordantly, our data (figure 3.11) suggest that cell death was especially higher in young
homozygotes than in heterozygotes. Caspase staining was mainly located in the periphery of
islets. Additionally, caspase and insulin staining did rarely match. This staining pattern can be
found throughout literature in mouse and rat models (Reddy et al., 2003).
Thus, it has to be suspected that caspase-3 staining covered primarily non-beta-cells or dedif-
ferentiated beta-cells. Beta-cell dedifferentiation is known to play an important role in beta-cell
dysfunction. In the pathophysiology of diabetes, an early switch in beta-cell gene expression
leads to downregulation of physiologically active genes and upregulation of suppressed genes.
Beta-cells lose their differentiation and cease to produce insulin. (Weir and Bonner-Weir, 2004).
Studies indicate that beta-cell dedifferentiation is closely connected to a loss of Forkhead box
protein O1 (FOXO1) expression. Transcription factor FOXO1 has influence on beta-cell mass
and stress response, as well as cell differentiation in several cell types. While dedifferentiated
beta-cells show reduced FOXO1 expression, they express transcription factors usually found in
progenitor cells. These findings were confirmed for islets of db/db mice (Talchai et al., 2012).
At states of severe hyperglycaemia, dedifferentiation is accelerated. Thus, the concept of beta-
cell dedifferentiation gives an explanation for the loss in insulin producing cell mass while
beta-cell apoptosis is an rarely observed event in db/db specimen.
An explanation for the loss in islets due to beta-cell apoptosis and dedifferentiation can be
found in the concepts of glucotoxicity and lipotoxicity (section 1.2.5). The formation of ROS,
the triggering of stress-sensitive pathways such as signalling via NF-kappaB, glucose autoxida-
tion and the alterations on the gene level caused by chronic hyperglycaemia have a detrimental
impact on beta-cells and glucose metabolism. It was reported that beta cells in db/db mice
have a reduced expression of GLUT2 and thereby an impaired reaction to serum blood glucose
(Thorens et al., 1992). In Zucker rats defective reaction to glucose in combination with hyper-
glycaemia was observed when the ratio of GLUT2-negative beta-cells exceeded 40 % (Johnson
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et al., 1990). Those findings might account for loss in proliferation and insulin secretion in age-
ing homozygotes. Furthermore, a study with New Zealand Obese (NZO) mice revealed results
similar to those in homozygote db/db animals. NZO mice were rendered obese by diet and
then separated into two groups, receiving either a carbohydrate-free diet or a diet containing
carbohydrates. Compared to the control group, obese NZO mice fed with carbohydrates had
high blood glucose levels combined with a reduced pancreatic insulin content, down-regulated
GLUT2 receptors on beta-cells, increased beta-cell apoptosis and decreased Pdx1 and FOXO1
expression (Kluth et al., 2011).
4.2 Trx family protein expression in dependency of the dia-
betic environment
We explored the expression of Trx family proteins in our research animals over time. The stain-
ings of thioredoxins (figure 3.13), peroxiredoxins (figure 3.14) and glutaredoxins (figure 3.15)
revealed varying expression patterns and differences between homozygote and heterozygote an-
imals.
We focused on Grx1 and 5, because of all analysed redoxins their expression was most pro-
nounced in pancreatic islets. All other redoxins merely showed a faint expression in both ho-
mozygote and heterozygote islets. Moreover, there was a marked difference in Grx1 and 5
expression between islets of both groups of mice. No such evident distinction was apparent for
any other redoxin. Apart from that, both isoforms appeared to be promising targets to study
because of their common features and differences. While they belong to the same subsystem
of glutathione dependent Trx family proteins, the glutaredoxins, they differ regarding their in-
tracellular location and purpose and their catalytic activity. Grx1, on the one hand, is a mainly
cytoplasmatically located glutaredoxin with impact on cell differentiation and several transcrip-
tion factors, expressing high catalytic activity in the thiol-disulfide exchange. The main task of
Grx5, on the other hand, is maintaining iron homeostasis in the cell. It is located in the mito-
chondria and required for the assembly of iron-sulfur clusters and thereby also for the activation
of several respective enzymes.
Our qRT-PCR data for Grx1 revealed that the level of Grx1 expression varied with the amount
of islets and the mean islet area. Between 6th and 18th week there was a gap in the number of
islets as well as in Grx1 expression in homozygotes. Mean islet area was largest at this time
point. Heterozygotes, on the contrary, showed a significantly higher, stable expression of the
protein (figure 3.16) as well as higher protein levels (figures 3.17 and 3.18). Since Grx1 is
anti-apoptotic and functions as a promotor for cell proliferation (section 1.3.3), the expression
of Grx1 may facilitate the generation of new islets in db/db animals in response to hypergly-
caemia. Similar effects were witnessed in hearts of diabetic mice where increased Grx1 levels
achieved by gene therapy prevented cardiac damage caused by ischaemia in diabetic mice (Lekli
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et al., 2010).
The expression of Grx5 in db/db mice followed the same downward trend as the expression of
the INS-1 gene (figure 3.19). We found a constant decrease in both groups of animals with the
heterozygotes having a higher expression in general (figures 3.20 and 3.21). The function of
the redoxin was studied in yeast mutants lacking Grx5. They were found to be much more sus-
ceptible to oxidative and osmotic stress. They suffered from increased ROS, an accumulation
of iron in the cell and an inactivation of enzymes containing Fe-S clusters whose generation
requires Grx5 (Rodrı´guez-Manzaneque et al., 1999, 2002). The role of Grx5 in obese db/db
mice might be similar, as ageing animals suffer from islet apoptosis and dysfunction while the
Grx5 expression recedes.
In conclusion, heterozygote db/+ mice had a higher gene expression for Grx1, Grx2 (data shown
in appendix, figure 11.5) and Grx5. Also the protein level was found to be higher for Grx1 and
5 (section 3.6.1.2 and 3.6.2.2). Especially for Grx5 our results revealed a strong correlation
with age. Both diabetic db/db and non-diabetic db/+ mice exhibited a drastic decrease in Grx5
gene expression, which leads to the assumption that Grx5 is even more dependent on age than
on diabetes and obesity, although non-diabetic lean heterozygotes expressed more Grx5 than
their diabetic obese homozygote counterparts. Grx1, by contrast, seems to correlate with the
metabolic situation, exhibiting varying expression together with marked alterations of islet area
and diabetes in homozygote db mice.
These findings suggest that there is a correlation between the Trx family of proteins on the one
hand and the obese phenotype and diabetic environment on the other hand.
Researchers have begun to gain insight into that link. It was revealed that NADPH promotes in-
sulin secretion in MIN6 cells and isolated islets of rats and that Grx1 and Trx1 have influence on
the process. While Grx1 has a positive effect on NADPH-mediated exocytosis of insulin, Trx1
was found to oppose its release (Ivarsson et al., 2005). Furthermore, another study showed that
Grx1 knockout in INS-1 cells and rat islets results in an impaired insulin secretion (Reinbothe
et al., 2009). A protective effect in db/db mice overexpressing Trx1 could also be detected. The
gain in body weight and the reduction of insulin secretion were counteracted in those animals
and thus the progression of hyperglycaemia was slowed down (Yamamoto et al., 2008). More-
over, studies suggest a positive effect of Peroxiredoxins. Prx3 is an antagonist against several
noxious agents and a lack of the protein affects insulin secretion in rat insulinoma cells (Wolf
et al., 2010). Similar protection was witnessed for Prx4 (Ding et al., 2010).
These studies suggest that the observed differences between homozygote and heterozygote db
mice including phenotype, blood glucose levels, islet count, area, proliferation and apoptosis,
as well as insulin expression are not merely a result of their phenotype, but also of a diverging
redoxin expression. Furthermore, the significance of Trx family proteins in humans has been
investigated in several studies. A lowered Grx1 activity was observed in platelets of patients
suffering from diabetes (Di Simplicio et al., 1995), and Japanese researchers detected a corre-
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lation between a polymorphism of the human thioredoxin gene (TXN) and diabetes (Ikegami
et al., 2008). Besides, diabetic patients showed increased expression of Txnip, which is up-
regulated by glucose (Parikh et al., 2007) and prevents proper Trx functioning (Schulze et al.,
2004).
We did not only observe lower Grx expression in homozygote db mice, but also increased
basal ROS levels (section 3.7). Stimulation by glucose and TNF-alpha lead to even higher for-
mation of reactive species, especially in homozygotes. On the one hand, ROS occur in aerobic
metabolism, represent physiological reactions of a healthy cell, and an elevation implies an
increased metabolic activity (Fleury et al., 2002). On the other hand, an imbalance between re-
active species and defense mechanisms causes oxidative stress. Due to this imbalance, cells take
damage and ROS connote with harmful effects (Evans et al., 2002). It is to be suspected that
db/db islets underwent pronounced metabolism in these diabetic obese animals, represented
in our experimental setup by exposure to glucose and TNF-alpha. Even at basal conditions,
they featured elevated ROS. At a certain stage, the formation of ROS could not be countered
anymore by the inherently weak cellular defense mechanisms of the beta cell, resulting in cell
damage and apoptosis. In contrast, db/+ islets featured lower basal and stimulated ROS forma-
tion, indicating physiological cell metabolism and an operational redox regulation.
4.3 Adipokines in the pathophysiology of diabetes mellitus
type 2
Another main influence factor which has to be considered is the effect of messengers released
by white adipose tissue (WAT). Autocrine, paracrine and endocrine regulation is exerted by
so-called adipokines and adipose-derived hormones. Such products of WAT had already been
described in the 1980s (Flier et al., 1987). In 1994, researchers identified leptin as an adipose-
derived hormone (Zhang et al., 1994) and subsequently, its receptors, too (Tartaglia et al., 1995).
Being mainly produced by WAT, the amount of leptin correlates with fat mass and is thus ele-
vated in obese subjects (Fain et al., 2004). Accordingly, obese animal models such as the db/db
mouse express high levels of ob mRNA and leptin (Maffei et al., 1995). As a key regulator of
energy homeostasis (Friedman and Halaas, 1998), leptin has an impact on glucose metabolism
and on the beta-cell. On the one hand, leptin inhibits the secretion of insulin (Kulkarni et al.,
1997) as well as insulin gene expression (Seufert et al., 1999), but on the other hand, insulin
stimulates leptin secretion (Laferre`re et al., 2002) and gene expression (Moreno-Aliaga et al.,
2001). Those findings lead to the postulation of a so-called adipo-insular axis which consists of
a feedback loop between WAT and the pancreas (figure 4.1).
58
4 Discussion
Brain
WAT beta-cell
Insulin
+
Leptin
-
-
-
appetite
Leptin
Figure 4.1: The adipo-insular feedback loop. Apart from the regulation between WAT and the
pancreas, leptin restricts appetite and the autonomous nervous system inhibits in-
sulin secretion, too (Kieffer and Habener, 2000).
As a confirmation of this hypothesis, a normalisation of body weight, body fat content, food
intake, blood glucose level and hyperinsulinaemia is achieved within a few weeks by adminis-
tering leptin to ob/ob mice. Furthermore, an intraperitoneal or intracerebroventricular admin-
istration of the hormone on homozygote db/db animals has no effect due to the defect of the
Ob-Rb receptor (Halaas et al., 1995), while pregnant db/+ animals show benefit, namely an ease
of the symptoms of gestational diabetes mellitus (Yamashita et al., 2001).
Accordingly, a supraphysiological release of insulin resulting in hyperinsulinaemia, typical for
the pathophysiology of diabetes mellitus type 2 (section 1.2.5), is found in ob/ob and db/db
mice alike. This stage of the disease is reached already at a young age in those animals and pre-
cedes obesity and insulin resistance (Coleman and Hummel, 1974). When we started observing
our research animals, they were already past this stage and presented beta-cell dysfunction and
failing insulin secretion.
An important observation that has to be considered in this context is leptin resistance. Both cen-
tral as well as peripheral resistance (Halaas et al., 1997), including the beta-cell (Seufert, 2004),
have been observed. Impaired leptin signalling, as functionally present in db/db animals, poses
an explanation for the fact that there is no effect of leptin in obese subjects from a certain
point in the development of obesity onwards. Although impressive effects of exogenously ad-
ministered leptin, including weight loss, were described in two children suffering from leptin
deficiency (Farooqi et al., 2002), no significant reduction of weight was found in a randomized,
placebo-controlled trial with 284 subjects (BMI 27 to 37 kg m−2, age 46.8±10.4 years) in 2005
(Zelissen et al., 2005).
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However, our experiments with MIN6-cells exposed to leptin showed no regulation of neither
insulin nor Grx (section 3.8). Regarding these findings, it has to be taken account of the fact
that we used high passage MIN6-cells (passage 70 to 80), which are known to be non-gluco-
responsive (Cheng et al., 2012). Thus, our results suggest that glucose is a required cofactor
in leptin-triggered regulation of insulin and redoxins. On the one hand, we observed a marked
decline in insulin secretion when MIN6 cells were exposed to hypoxia. On the other hand, our
experiments were missing the physiological and biochemical context of the islet of Langerhans
as a micro organ, like in experiments carried out with isolated islets.
Apart from the regulation of energy homeostasis, leptin is also a modulator of immune re-
sponses. The phagocytic function of macrophages of ob and db mice was already evaluated in
1998. Results revealed that significantly less macrophages from homocygote animals were ac-
tive in comparison to heterozygotes. Furthermore, application of leptin improved phagocytosis
in ob/ob, ob/+ and db/+ animals, whereas db/db macrophages turned out to kill significantly
less targets, suggesting a strong effect of administered leptin. Those observations could also
be confirmed in vivo when labeled E. coli bacteria were injected into ob animals. Clearance
was significantly more efficient in lean control animals, suggesting an important function of
leptin in cellular immune defence (Loffreda et al., 1998). Moreover, a study revealed a strong
effect of leptin on the expression of inflammation-related genes. Fibrinogen-beta, Lipocalin-2,
manganese-dependent superoxide dismutase, pancreatitis-associated protein, preprotachykinin-
1 and tissue-type plasminogen activator were shown to be upregulated by leptin in insulinoma
cells. Its authors emphasize that those transcripts encode for both protective as well as toxic
products (Hekerman et al., 2007). It is still a matter of research to what extent and under which
conditions leptin carries out a protective function and when its effects are rather harmful. Some
researchers were able to present protective effects, for example a certain resistance against apop-
tosis induced by fatty acids in Zucker diabetic rat (Shimabukuro et al., 1998) and a prolongation
of viability of isolated rat beta-cells by administration of leptin (Okuya et al., 2001). However,
there are opposing results. An in-vitro study targeting human islets revealed a leptin-induced
increase in beta-cell production of interleukin 1 (IL-1) while a decrease in IL-1 receptor an-
tagonist (IL-1Ra) was observed. The authors demonstrated a protective effect of exogenously
administered IL1Ra while antagonising it resulted in corrupted insulin release and increased
apoptosis measured by caspase-3 activation and fragmentation of DNA (Maedler et al., 2004).
Altogether it can therefore be suspected that leptin plays a major role in the pathophysiology
of diabetes and is certainly involved in pathologies of db and ob animals, giving an explanation
for the fact that db mice present very early changes in comparison with lean phenotypes.
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4.4 Limitations
Some limitations have to be considered. On the one hand, there is a limited possibility of trans-
ferring results gained from mouse experiments to human subjects. The animals’ metabolism
runs much faster, resulting in an accelerated cell cycle and a quick progress of the pathologies
associated with obesity and hyperglycaemia. Also, the complete resistance to leptin represents
an extreme genetic variant which is generally not present in human diabetic patients. On the
other hand, the choice of our model allowed us to observe a distinct phenotype which take years
to develop in human subjects.
When we started our observations, homozygote animals already displayed marked phenotypi-
cal alterations. Body weight, blood glucose level, islet area and INS-1 expression had already
been pathological. Starting our study at an earlier age would thus have enabled us to observe
early development of especially homozygote db/db animals. By contrast, we finished our study
at 18 weeks of age. Regarding our data for heterozygotes, it appears promising to follow their
development beyond 18 weeks of age. They weighed more than wild type animals and their
blood glucose level and islet area followed an upward trend while a decrease in insulin and Grx
expression was noticed, leaving open the question whether they would eventually progress into
diabetes like their homozygote counterparts. Nonetheless, the selected time period allowed us
to sufficiently study the selected mouse model and outline the differences between db/db and
db/+ animals. In the consulted literature, db animals were usually studied from 5 to 16 weeks
of age on average. Thus, we concluded that a respective observation period can be considered
sufficient for our intended analysis of Trx family proteins and the islets of Langerhans. Rarely,
animals were kept for longer than 20 weeks. The progression of the body weight, blood glucose
level including HbA1c and the morphology of islets appeared to show now more marked shift
from 18 weeks of age onwards in homozygotes. It must also be taken into account that there
was a logistical limitation regarding the start of our study. Charles River provided the animals at
the age of 5 weeks. After being deployed to our animal housing, the mice were given time to get
accustomed to their new environment. Thus, 6 weeks of age appeared to be a reasonable start.
Starting earlier would subsequently have required us to breed the animals ourselves, which was
not possible in our laboratory.
Regarding our methods, it has to be taken into account that we used qRT-PCR, not revealing
the absolute gene expression levels. Despite not knowing to what exact extent gene expression
was constrained in the studied research animals, we were able to point out the severe impact
of a homozygote db/db mutation on INS-1 and Grx expression in islets by comparison with
heterozygotes.
We also did not determine absolute protein levels for insulin and redoxins in pancreatic tissue,
but established a semiquantitative approach using normalised pictures taken of immunostained
tissue (section 2.2.2). The data were consistent with results gained from PCR and plasma in-
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sulin levels as well as pancreatic insulin content (section 4.1).
For the immunohistological analysis of islets, an interval of 140 µm was maintained between
sections in order to avoid multiple inclusion of identical islets. During our studies a mean islet
area of 200 µm was detected for 12 weeks old homozygotes. Thus, measuring the same islet
twice was avoided by careful observation of consecutive slides.
We have not succeeded in quantitatively analysing apoptosis in islets. A TUNEL kit was used
for staining, but there were too few TUNEL positive cells for a reasonable evaluation. Corre-
sponding results to our qualitative approach were mentioned in section 4.1.
4.5 Conclusion
In summary, we defined the pancreatic pathologies of obese, diabetic and leptin-resistant ho-
mozygote db/db mice and delineated them to their lean, non-diabetic heterozygote counterparts.
In addition, we demonstrated a significantly different expression of Trx family proteins between
both groups of mice, especially a lower one for Grx1 and 5 in homozygotes, which has not yet
been described before to our knowledge. Moreover, we detected an increased formation of ROS
in pancreatic islets of db/db animals. A direct influence of leptin on Grx and insulin protein lev-
els could not be observed.
On the one hand, we suspect that obesity with all its implications, such as elevated reactive
species, is an important factor behind early blood glucose dysregulation in db/db mice. The
adipo-insular feedback loop is interrupted and insulin secretion cannot be inhibited by leptin
and satiety after ingestion. On the other hand, insulin secretion and beta-cell survival is im-
paired in several ways. A lack of Grx 1 is connected to reduction of numerous transcription
factors, for example Nf-kappaB, AP-1, CREB, Nuclear Factor I and ASK1. Additionally, the
redoxin is missing in the Grx-pathway, interfering with cellular antioxidant capacity, and its
role in promoting exocytosis of insulin is affected as well. Reduced levels of Grx5 cause iron
overload as well as inactivation of proteins requiring iron-sulphur clusters, including enzymes
of the Krebs cycle. The amount of GLUT2 is reduced under oxidative stress. Enzymes of the
Krebs cycle as well as anaplerosis and cataplerosis are corrupted directly. Also, deleterious ef-
fects on ATP-sensitive potassium channels have been observed. Taken together, these influence
factors deteriorate the beta-cells’ physiological response to glucose. A summary is given in
figure 4.2.
62
4 Discussion
Figure 4.2: Implications of our results on the physiology of insulin secretion of the beta-cell in
correspondence with literature. a) Under oxidative stress, the amount of GLUT2
in the beta-cell’s membrane was found to be decreased. b) Mitochondria develop
pathologies regarding morphology and function. Anaplerosis and cataplerosis of
the Krebs cycle are corrupted and its enzymes are directly inhibited by oxidants. A
lack of iron-sulphur clusters caused by a deficiency of Grx5 further adverses pro-
duction of ATP. Thus, a functional isolation of glucose uptake, processing and ATP
production from ATP-sensitive potassium channels is observed. c) Those channels
are furthermore directly and indirectly harmed by free radicals. d) Also, a shortage
of Grx1 is supposed to impair exocytosis of insulin. While these facts contribute
to defective insulin secretion, leptin exhibits an inhibitory effect. e) However, in
leptin-resistant db/db mice as well as in adipose subjects the hormone cannot exert
its function, resulting in enhanced insulin secretion.
In conclusion, we propose that the redox state of the beta-cell and Grx1 and 5 are closely
connected to impaired insulin secretion and destruction of the islets of Langerhans.
However, the mechanisms underlying induction and depletion of redoxins as well as their role
in protection and regulation of cellular processes require further investigation. Although there
are several studies with animals over- or underexpressing Trx family proteins, leading to partly
severe, and partly mild phenotypical consequences (section 1.3), the exact role of redoxins in
diabetes remains vague. Pancreas or beta-cell specific knock-down or -up models could supply
powerful tools to illuminate the functions of those factors. On the one hand, the effects of a
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lack of Grx1 are suspected to depend on the respective target proteins. Mice deficient in Grx1
show neither increased myocardial damage after ischemia, nor significantly higher lung injury
after hyperoxia. Embryonic fibroblasts of Grx1 deficient mice are protected against apoptosis
induced by TNF-alpha, and are more susceptible to deleterious effects of diquat and paraquat
but not to those of H2O2 and diamide (Ho et al., 2007). On the other hand, growth defects, iron
overload and increased susceptibility to oxidants are well documented in yeast mutants lack-
ing Grx5 (Rodrı´guez-Manzaneque et al., 2002). Thus, observation of redoxin expression and
protein levels as well as blood glucose level and development of islets, including morphology,
islet insulin content, proliferation and apoptosis in such a pancreas or beta-cell specific animal
model should provide important information regarding the role of redoxins. A conceivable ap-
proach could be to chose beta-cell specific Grx1 and 5 knockout models, respectively, and stress
homozygotes and heterozygotes by high-carbohydrate diet to induce hyperglycaemia and ox-
idative imbalance. Based on our data, we predict that decreased levels of Grx1 or 5 will lead to
elevated islet apoptosis and dedifferentiation, defective insulin secretion and thereby corrupted
glucose homeostasis, while elevated levels of Grx1 or 5 should have rather protective effects.
Furthermore, parameters which give information about the redox state of the pancreas and iso-
lated beta-cells should be investigated. GSH / GSSG levels, glutathionylation of proteins, redox
modifications of the proteome and identification of targets for redoxins should provide more
detailed insights into connections between diabetic pathologies and impaired redox signalling.
Moreover, it has to be discussed whether Trx family proteins could be used as diagnostic in-
dicators of early prediabetic stages. Recently, a study was carried out to determine whether
there is a difference in Grx1 activity and expression in blood plasma of healthy subjects com-
pared to patients with abnormal glucose tolerance. 14 such patients diagnosed with IFG, IGT
or diabetes type 2 according to fasting blood glucose or OGTT (median age 66.6 years, median
fasting blood glucose 6 mmol l−1) who had not received antidiabetic medication previously or
during the study were compared to ten healthy subjects (median age 25.5, median fasting blood
glucose 4.9 mmol l−1). A Grx1 activity assay kit was used in order to measure Grx1 activity
after over night fasting and after OGTT. Baseline Grx1 activity was significantly higher among
patients. However, healthy subjects presented a significant increase in Grx1 activity two hours
after OGTT while a slight decrease was found in the patients. Grx1 was further analysed us-
ing ELISA and Western blot, again revealing significantly lower levels in healthy subjects in
comparison to patients. No influence of OGTT could be detected here (Du et al., 2013). Our
data suggest that heterozygote animals express homozygotes’ pathologies in an attenuated and
delayed form, especially in terms of body weight, blood glucose level, INS-1 expression and
mean islet area. Thus, heterozygote db/+ mice might be compared to patients suffering from
abnormal glucose tolerance in the previously mentioned study, presenting an explanation for
their elevated Grx levels in comparison to diabetic homozygotes. Furthermore, similar results
were found for Trx in a study including 174 patients diagnosed with type 2 diabetes (87 males,
age 61±13; 87 females, age 61±14 years) and 16 healthy subjects (9 males, 7 females, age
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60±16 years). Trx levels in participants’ serum measured by ELISA were found to be signifi-
cantly higher in patients (Kakisaka et al., 2002).
In order to find out at what developmental stage redoxin levels show measurable differences
between diabetic and non-diabetic animals investigation should begin earlier. While we started
observing mice when they had already displayed distinct pathologies, the involved mechanisms
causing and following altered redoxin levels should become clearer in specimen with less ad-
vanced phenotypical changes. Abnormally high plasma insulin levels for example can already
be observed in 10 to 14 days old animals (Coleman and Hummel, 1974). We consider a Pdx1
knockout model to be a revealing approach. Homozygote animals lacking Pdx1 do not develop
a pancreas and die days after birth (Jonsson et al., 1994). In adult animals, Pdx1 is known to
transactivate the insulin promotor (Ohlsson et al., 1993). Mice with a heterozygote inactivation
of Pdx1 (Pdx1+/-), similar to human MODY type 4, were previously compared to healthy lit-
termates (Pdx1+/+). There were no significant differences in body weight between both groups
of mice. Heterozygotes presented elevated blood glucose levels after glucose tolerance tests
and lower insulin secretion when pancreata were perfused with glucose in situ. Furthermore,
isolated islets from heterozygote animals were of lower count and appeared damaged, which
was confirmed by a histologically corrupted islet architecture. Nonetheless, islets did not show
impaired insulin release in reaction to glucose, but exhibited a significant increase in apoptosis
when cultured in 5 mM or 10 mM glucose for 72 hours which resulted in significantly lowered
islet count and mass from 5 weeks of age onwards (Johnson et al., 2003). Taken together,
Pdx1+/- animals displayed obvious pathologies of glucose homeostasis which were not yet no-
table in single beta-cells apart from elevated apoptosis. Therefore, such an animal model should
provide an insight into early defects of redox signalling, especially if inactivation of Pdx1 was
achieved after birth, for example on day 5. Thereby prenatal influences of defective Pdx1
function were neutralised and the experiment would focus on the beginning of the previously
described pathologies.
As Trx family proteins increasingly gain attention by many researchers, their role in diabetes
mellitus will certainly be untangled in the near future. Research will hopefully lead to new
therapeutical strategies on the basis of those findings. The role of adipose-derived hormones like
leptin, in combination with Trx family proteins, might provide new options for future therapy,
in the complex and yet not fully explored pathophysiology of adipositas and diabetes mellitus
type 2, as well.
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5 Summary
Over 300 million people worldwide are suffering from diabetes mellitus type 2, a complex
disease consisting of decreased insulin sensitivity, increased gluconeogenesis, impaired insulin
secretion and apoptosis of the beta-cells. Furthermore, chronic inflammation and oxidative
stress caused by free radicals play a major role in its pathophysiology.
A defence mechanism against oxidative stress is redox signalling. Major actors in re-establishing
redox homeostasis are thioredoxin family proteins, including glutaredoxins, peroxiredoxins and
thioredoxins. They modify their substrates by oxidation and reduction reactions.
We studied the consequences of an obese phenotype on the Islets of Langerhans in comparison
to the lean one. As an animal model we chose db mice. Homozygotes of this strain of C57BL/6
mice suffer from leptin resistance due to a mutation in the transmembrane leptin receptor Ob-
Rb, developing an obese, diabetic phenotype. We delineated homozygotes to their heterozygote
counterparts and explored the distinctions in vital parameters, islets and redoxin expression.
Blood glucose and body weight were measured weekly from 6 to 18 weeks, confirming obe-
sity and diabetic metabolism in homozygotes. Islet isolation and pancreatectomy were carried
out at 6, 12 and 18 weeks. Homozygotes held significantly more islets, larger mean islet area
and higher proliferation rates as well as increased apoptosis and failing secretion of insulin.
Heterozygotes in contrast had higher insulin expression together with stable blood glucose and
body weight.
Trx family proteins distinguished both groups of animals further, displaying varying expression
patterns in immunohistology. We analysed gene and protein expression of Grx1 and 5 more de-
tailed and found significantly higher expression in heterozygote animals. Grx1 levels fluctuated
together with the metabolic situation in homozyotes while Grx5 decreased with age.
Formation of reactive oxygen species was measured in isolated islets and revealed elevated ROS
in db/db specimens.
To investigate the role of leptin, we cultivated non-gluco-responsive MIN6 cells with this
adipose-derived hormone using different concentrations. Protein levels for Grx1 and 5 as well
as insulin measured by ELISA turned out to be not influenced by leptin without glucose as a
cofactor.
We demonstrated that Trx family protein expression differs significantly between the obese,
diabetic and the lean phenotype and that they are connected to the progress of obesity and hy-
perglycaemia. In conclusion, we propose that the redox state of the beta-cell and Grx1 and 5 are
closely connected to impaired insulin secretion and destruction of the islets of Langerhans.
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6 Zusammenfassung
U¨ber 300 Millionen Menschen weltweit leiden an Diabetes mellitus Typ 2. Die komplexe Pa-
thophysiologie besteht aus verringerter Insulinsensitivita¨t, erho¨hter Glukoneogenese, gesto¨rter
Insulinsekretion sowie Apoptose der Beta-Zellen. Zudem spielen eine chronische Entzu¨ndung
sowie oxidativer Stress eine entscheidende Rolle. Ein Verteidigungsmechanismus gegen letzte-
ren stellen redox-regulierte Signalwege dar. Proteine der Thioredoxin-Familie, welche Gluta-,
Peroxi- und Thioredoxine beinhaltet, stellen die redox-Homeostase der Zelle wieder her, in-
dem sie ihre Substrate reduzieren. Wir untersuchten die Auswirkungen des adipo¨sen Pha¨notyps
auf die Langerhansschen Inseln im Vergleich zum schlanken anhand der db-Maus. Homozygo-
te dieses Stammes von C57BL/6 Ma¨usen sind aufgrund einer Mutation im transmembrano¨sen
Leptinrezeptor Ob-Rb durch Leptinresistenz gekennzeichnet und entwickeln einen adipo¨sen,
diabetischen Pha¨notyp. Wir beschrieben die Unterschiede zwischen diesen und ihren heterozy-
goten Artgenossen in Bezug auf Vitalparameter, Langerhans-Inseln und Expression der Redo-
xine. Blutzucker und Ko¨rpergewicht wurden wo¨chentlich im Alter von 6 bis 18 Wochen gemes-
sen. Die Resultate besta¨tigten Adipositas und diabetische Stoffwechsellage der Homozygoten.
Mit 6, 12 und 18 Wochen wurden Inselisolation und Pankreatektomie durchgefu¨hrt. Homozy-
gote Tiere besaßen signifikant mehr Inseln, eine gro¨ßere mittlere Inselfla¨che und ho¨here Prolife-
rationsraten sowie eine gesteigerte Apoptose. Die Heterozygoten hatten die gro¨ßere Insulinex-
pression sowie stabilen Nu¨chternblutzucker und Gewicht. Die unterschiedliche Expression der
Redoxine unterschied beide Gruppen weiter. Wir analysierten die Gen- und Proteinexpression
von Grx1 und 5 im Detail und fanden eine signifikant ho¨here Expression in heterozygoten Tie-
ren. In den Homozygoten schwankte das Niveau von Grx1 mit der Stoffwechsellage, wa¨hrend
Grx5 mit dem Alter korrelierte. Die Entstehung von reaktiven Sauerstoffspezies wurde in iso-
lierten Inseln gemessen und zeigte eine vermehrte Bildung in db/db-Tieren. Um die Rolle des
Leptins zu untersuchen, kultivierten wir glukoseunempfindliche MIN6-Zellen mit verschiede-
nen Konzentrationen dieses Proteohormons. Die Proteinlevel von Grx1 und 5 sowie Insulin, ge-
messen per ELISA, zeigten keinen erkennbaren Einfluß des Leptins ohne Glukose als Kofaktor.
Wir demonstrierten, dass die Expression von Proteinen der Thioredoxin-Familie den adipo¨sen,
diabetischen und den schlanken Pha¨notyp signifikant unterscheidet, und dass sie mit dem Vor-
anschreiten der Adipositas und der Hyperglyka¨mie in Verbindung stehen. Zusammenfassend
postulieren wir, dass der redox-Status der Beta-Zelle sowie Grx1 und 5 eng mit einer gesto¨rten
Insulinsekretion und einer Zersto¨rung der Langerhansschen Inseln zusammenha¨ngen.
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7 List of abbreviations
Ala Alanine
AOK Allgemeine Ortskrankenkasse
ASK1 apoptosis signaling kinase 1
ATP adenosine triphosphate
BMI body mass index
BSA bovine serum albumin
Cys cysteine
DCFH-DA 2,7-dichlorofluorescein diacetate
DDG Deutsche Diabetes Gesellschaft (German diabetes association)
DDP-4 dipeptidyl peptidase-4
DMEM Dulbecco’s Modified Eagle Medium
DMSO dimethylsulfoxide
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
ELISA enzyme-linked immunosorbent assay
FBS fetal bovine serum
FOXO1 Forkhead box protein O1
GDA German diabetes association
GLP-1 glucagon-like peptide-1
Gln Glutamine
GLUT2 Glucose transporter 2
Gly Glycine
GR Glutathione reductase
Grx glutaredoxin
GSH Glutathione (reduced)
GSSG Glutathione (oxidised)
HRP Horseadish peroxidase conjugated
IFG Impaired fasting glucose
IGT Impaired glucose tolerance
IL1 Interleukin 1
JNK c-Jun N-terminal kinase
IL-1 interleukin-1
IL-1Ra IL-1 receptor antagonist
MAP Mitogen-activated protein
MIN6 Mouse insulinoma, 6th subclone
MODY maturity onset diabetes of the young
NAPDH nicotinamide adenine dinucleotide phosphate
NRX Nuceloredoxin
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7 List of abbreviations
NZO New Zealand Obese
OGTT oral glucose tolerance test
PBS phosphate buffered saline
PCR polymerase chain reaction
Pdx1 Pancreatic duodenal homeobox-1
Phe Phenylalanine
Pro Proline
Prx peroxiredoxin
qRT-PCR quantitative real-time polymerase chain reaction
RNS reactive nitrogen species
ROS reactive oxygen species
Ser Serine
TNF-alpha tumor necrosis factor-alpha
TRIS tris(hydroxymethyl)aminomethane
Trx thioredoxin
TrxR thioredoxin reductase
TXN human thioredoxin gene
Txnip Thioredoxin-interacting protein
Tyr Tyrosine
VEGF vascular endothelial growth factor
WAT White adipose tissue
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11.1 Follow-up of the body weight and blood glucose level of
db/db and db/+ mice
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Figure 11.1: Follow-up of the body weight (n = 11 to 40 per timepoint).
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Figure 11.2: Follow-up of the blood glucose level (n = 11 to 36 per timepoint).
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11.2 Comparison between db/+ and wild type C57BL/6 mice
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Figure 11.3: Body weight comparison between db/+ and wild type C57BL/6 mice (n = 2 to 40
per timepoint).
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Figure 11.4: Blood glucose level comparison between db/+ and wild type C57BL/6 mice (n = 2
to 35 per timepoint).
87
11 Appendix
11.3 qRT-PCR results for Grx2 expression in isolated islets
6 12 18
0.000
0.002
0.004
0.006
0.008
db/db
db/+
***
**
age [wks]
n
o
rm
al
is
ed
 e
xp
re
ss
io
n
Figure 11.5: Gene expression of Grx2 (relative Grx2 expression normalised with beta-actin, n
= 4 to 6 per timepoint). It followed the same pattern as Grx5.
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